- ELV Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
DEF 14A Filing
Elevance Health (ELV) DEF 14ADefinitive proxy
Filed: 9 Apr 21, 4:30pm
☑ | Filed by the Registrant |
| About Anthem, Inc. | |
| Anthem is a leading health benefits company, striving to improve the health of humanity, and dedicated to improving lives and communities, and making healthcare simpler. Through its affiliated companies, Anthem serves more than 110 million people, including 42.9 million within its family of health plans. We aim to be the most innovative, valuable and inclusive partner. For more information, please visit www.antheminc.com or follow @AnthemInc on Twitter. | |
| |
| 2 | | | | 2021 Proxy Statement | |
| | | | | | | | | | | | | | | | | |
| | | Date and Time Wednesday, May 26, 2021 9:00 a.m. Eastern Daylight Time | | | | | Virtual Meeting Virtual-only meeting format, via live audio webcast at: www.meetingcenter.io/267442224 Meeting Password: ANTM2021 | | | | | Record Date Shareholders of record on March 22, 2021 are entitled to vote. | |
Proposals | | | Board Vote Recommendation | | | For Further Details | |
1. Election of Three Directors | | | “FOR” each director nominee | | | Page 11 | |
2. Advisory vote to approve the compensation of our Named Executive Officers | | | “FOR” | | | Page 41 | |
3. Ratification of Ernst & Young LLP as Auditors for 2021 | | | “FOR” | | | Page 72 | |
| | | | | | | | | | | |||||||||||||||||||
| You can vote in any of the following ways: | | |||||||||||||||||||||||||||
| | | Scan the QR code that is located on your proxy card, E-Proxy Notice or voting instruction form to vote WITH YOUR SMARTPHONE | | | | | Visit the website listed on your proxy card, E-Proxy Notice or voting instruction form to vote VIA THE INTERNET | | | | | Call the telephone number on your proxy card or voting instruction form to vote BY TELEPHONE | | | | | If you received printed proxy materials, sign, date and return your proxy card or voting instruction form in the envelope provided to vote BY MAIL | | | | | Log in to the live audio webcast with your control number to vote ONLINE during the Annual Meeting | |
| Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Shareholders to be held on May 26, 2021. The Notice of Annual Meeting of Shareholders, Proxy Statement and 2020 Annual Report on Form 10-K are available at: www.envisionreports.com/antm. | |
| | | | ||
| | | | ||
| | | Anthem, Inc. Notice of Annual Meeting of Shareholders | | |
| | | Proxy Statement Summary | | |
| | | Corporate Governance | | |
| | | | ||
| 12 | | | The Board of Directors | |
| 12 | | | | |
| 12 | | | | |
| 13 | | | | |
| 13 | | | | |
| 14 | | | | |
| 21 | | | The Board’s Role and Responsibilities | |
| 21 | | | | |
| 23 | | | | |
| 29 | | | | |
| 30 | | | | |
| 30 | | | Board Structure | |
| 30 | | | | |
| 30 | | | | |
| 30 | | | | |
| 31 | | | | |
| 34 | | | Board Practices, Processes and Policies | |
| 34 | | | | |
| 35 | | | | |
| 35 | | | | |
| 36 | | | | |
| 36 | | | | |
| 38 | | | | |
| | | Executive Officers of the Company | | |
| | | Executive Compensation | |
| 4 | | | | 2021 Proxy Statement | |
| Proposal 1 | | | | | | | | | | |
| Election of Directors | | | | | | | The Board recommends a vote FOR each director nominee. Page 11 | | ||
| Three directors have been nominated for election to hold office for a term to expire at the 2024 annual meeting: • Lewis Hay, III • Antonio F. Neri • Ramiro G. Peru | | | | |
| Proposal 2 | | | | | | | | | | |
| Advisory Vote to Approve the Compensation of Our Named Executive Officers | | | | | | | The Board recommends a vote FOR this proposal. Page 41 | | ||
| Our executive compensation program (the “Total Rewards” program) is designed to attract, engage, motivate and retain a talented team of executive officers and to appropriately reward those executive officers for their contribution to our business, our consumers and our shareholders. This proposal gives our shareholders the opportunity to express their views on the compensation of our Named Executive Officers (“Say-on-Pay”). | | | | |
| Proposal 3 | | | | | | | | | | |
| Ratification of the Appointment of Independent Registered Public Accounting Firm | | | | | | | The Board recommends a vote FOR this proposal. Page 72 | | ||
| The Audit Committee has selected Ernst & Young LLP to continue serving as our independent registered public accounting firm for the year ending December 31, 2021. | | | | |
| Our Purpose | |
| Improving the Health of Humanity. | |
| Our Mission | |
| Improving Lives and Communities. Simplifying Healthcare. Expecting More. | |
| Our Vision | |
| Be the most innovative, valuable and inclusive partner. | |
| Our Values | | ||||||||||||
| Leadership Redefine what’s possible. | | | Community Committed, connected, invested. | | | Integrity Do the right thing, with a spirit of excellence. | | | Agility Deliver today — transform tomorrow. | | | Diversity Open your hearts and minds. | |
| Total Operating Revenue ($ in billions) | | | Net Income Per Diluted Share | | | Adjusted Net Income Per Diluted Share* | |
| | | | | |
| • Medical membership grew by 1.9 million members to 42.9 million members as of December 31, 2020. • Total Operating Revenue growth of 17.1% was driven by growth across all of our businesses. • Income before income tax expense increased by 4.2% to $6.2 billion for 2020, as compared to $6.0 billion in 2019, while Operating Gain increased by 6.0% to $6.4 billion for 2020, as compared to $6.0 billion for 2019. Please refer to the GAAP reconciliation table in Annex A for information on Operating Gain. • Our closing stock price increased by approximately 6.3% from $302.03 on December 31, 2019 to $321.09 on December 31, 2020. In addition, the Company paid cash dividends totaling $3.80 per share in 2020. • We committed more than $2.5 billion in direct support and assistance in 2020 to ease the burden of the COVID-19 pandemic among our customers, care providers, associates and nonprofit partners. These efforts included extended cost-share waivers, premium credits, provider grants and community relief and supports. • We acquired Beacon Health Options, Inc., which was the largest independently held behavioral health organization in the country, in February 2020. • Anthem was named to the 2020 Dow Jones Sustainability North America and World Indices for the third consecutive year and was included on the Forbes JUST 100 list for a second consecutive year, continuing to rank first in the healthcare providers and services category. • Our solid performance is reflected in the compensation that our Named Executive Officers (“NEOs”) earned for 2020. | |
| 6 | | | | 2021 Proxy Statement | |
| Female Leadership in Key Roles | | | | Ethnically Diverse Leadership | | | | 9 of 10 Independent Directors | | | | 7 of 10 | |
| Independent Board Chair President and CEO Governance Committee Chair | | | | Compensation and Talent Committee Chair | | | | including 2 added since 2018 | | | | Directors are Diverse based on Gender and/or Ethnicity | |
Skills, Experiences and Attributes | | | Boudreaux | | | | Clark | | | | Dixon | | | | Hay | | | | Hill | | | | Jallal | | | | Neri | | | | Peru | | | | Schneider | | | | Tallett | |
CEO | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||
COO / Executive Leadership | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||
Insurance Industry | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
Finance / Capital Markets | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||
Healthcare Industry | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||
Marketing / Consumer Insights | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||
Technology | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||
Regulatory / Public Policy | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||
ESG | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||
Diversity | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | |||
| Board / Committee Independence | | | | Board Practices | | | | Accountability | |
| • Separate CEO and Independent Board Chair • Independent Board – 9 of 10 directors • Fully independent Audit, Compensation and Talent, Finance and Governance Committees | | | | • Annual Board, committee and individual director performance evaluations facilitated by an external party • Independent directors hold executive sessions • Board oversees Enterprise Risk Management activities | | | | • Majority voting for uncontested director elections • Proxy access for shareholder-nominated director nominees • Commitment to declassify the Board if the Blue Cross and Blue Shield Association requirement for a classified board is no longer applicable | |
| | | | | |
| Stock Ownership / Compensation | | |||
| • Significant director and executive stock ownership requirements and holding restrictions • Clawback policy for executive officers’ incentive compensation, including for reputational harm • Policy against short sales, hedging and pledging stock for directors and all associates, including our executive officers • Rigorous establishment and oversight of incentive measures, goals and pay / performance relationship • Say-on-Pay advisory vote conducted annually • Pre-established grant dates for equity awards to executive officers | | | • Limited executive perquisites • Double-trigger change-in-control provisions • No re-pricing of stock options or stock appreciation rights without shareholder approval • No change-in-control excise tax gross-ups • No guaranteed annual salary increases or bonuses • No compensation plans which encourage excessive risk taking • Independent compensation consultant | |
| 8 | | | | 2021 Proxy Statement | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | ||||
| Our Consumers | | | | Our Communities | | | | Our Associates | | | | Our Environment | |
| 60% of our healthcare spending in 2020 was in value-based care models Acquired Beacon Health, a behavioral health company, in 2020 Use of Live Health Online, our telehealth solution, and other telehealth services grew exponentially in 2020 | | | | $100 million pledged, with half to respond to COVID-19 and half to focus on social injustice and health inequities Over $45 million in active grants and sponsorships supporting over 500 nonprofit organizations Nearly 110,000 volunteer hours by our associates and $6.7 million donated through Associate Engagement Programs | | | | Over 90% of our associates participated in monthly “Culture Conversations” Our managers are diverse, with 63% being women and 35% being ethnically diverse in the U.S. Over 11,500 associates participate in our nine associate resource groups | | | | Commitment to 100% renewable energy by 2025 Over 40% reduction of our scope I and II greenhouse gas intensity since baseline 2013, achieving our first generation target Over 50% of our real estate is certified under third party sustainability programs | |
| | | | | | | | | | | | | | |
| | | | |||||
| Anthem, Inc. was named to the 2020 Dow Jones Sustainability North America and World Indices (DJSI). This marks the third consecutive year Anthem has been recognized by the DJSI for leadership in sustainability. | | | Anthem, Inc. was included in the Forbes JUST 100 list for a second consecutive year, continuing to rank first in the health care providers and services category. | | |||
| | | | | | |||
| Anthem, Inc. has a perfect 1/1/1 QualityScore from Institutional Shareholder Services (ISS), ranking first in the managed healthcare sector (as of February 2021). | | | Anthem, Inc. has been named a 2021 ESG Industry Top-Rated Company by Sustainalytics. In addition, Anthem is ranked first in the managed healthcare subindustry for lowest ESG risk and second out of nearly 500 global companies in the healthcare industry (as of February 2021). | |
| CEO | | | Other NEOs | |
| | | |
| 10 | | | | 2021 Proxy Statement | |
| PROPOSAL 1 | |
| Election of Directors | |
| | | |||
| | | The Board of Directors unanimously recommends a vote FOR Proposal 1, the election as directors of Lewis Hay, III, Antonio F. Neri and Ramiro G. Peru. | |
| 12 | | | | 2021 Proxy Statement | |
| • Integrity and Accountability • Financial Literacy | | | • Informed Judgment • Risk Oversight Ability | | | • Mature Confidence • High Performance Standards | |
| CEO | | | Contributes to the Board’s understanding of complex operations, business strategy and risk management and demonstrated leadership ability at the highest level | |
| COO / Executive Leadership | | | Contributes to the Board’s understanding of complex operations, business strategy and risk management and demonstrated leadership ability | |
| Insurance Industry | | | Contributes to the Board’s understanding of insurance operations and the industry’s complex regulatory requirements, as well as the competitive environment | |
| Finance / Capital Markets | | | Valuable for evaluating our financial reporting process, financial management and capital allocations (dividends / share repurchases / financings) | |
| Healthcare Industry | | | Contributes to the Board’s understanding of the providers of healthcare services and products and issues related to simplifying healthcare | |
| Marketing / Consumer Insights | | | Contributes to the Board’s understanding of changing market conditions and consumer trends and expectations | |
| Technology | | | Contributes to the Board’s understanding of technology, including the use of new technologies in providing our products and services, as well as cybersecurity risks | |
| Regulatory / Public Policy | | | Contributes to the Board’s understanding of complex regulatory and public policy issues facing us as a highly-regulated entity | |
| ESG | | | Contributes to the Board’s understanding of leading corporate governance practices and environmental and social sustainability initiatives | |
| Diversity | | | Gender and ethnic diversity provide different perspectives to the Board to foster innovation and inclusion | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Skills, Experiences and Attributes | | | | Boudreaux | | | | Clark | | | | Dixon | | | | Hay | | | | Hill | | | | Jallal | | | | Neri | | | | Peru | | | | Schneider | | | | Tallett | |
| CEO | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||
| COO / Executive Leadership | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||
| Insurance Industry | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| Finance / Capital Markets | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||
| Healthcare Industry | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||
| Marketing / Consumer Insights | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||
| Technology | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||
| Regulatory / Public Policy | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||
| ESG | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||
| Diversity | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 14 | | | | 2021 Proxy Statement | |
| Age: 65 Director Since: 2013 Committees: Audit (Chair) Finance Skills, Experiences and Attributes • CEO • COO / Executive Leadership • Finance / Capital Markets • Marketing / Consumer Insights • Technology • Regulatory / Public Policy • ESG | | | Lewis Hay, III Background Lewis Hay, III has been a director of the Company since July 2013. Mr. Hay has served as an operating advisor at Clayton, Dubilier & Rice, LLC (private equity investment firm) since 2013. Mr. Hay retired as Executive Chairman of NextEra Energy, Inc. (“NextEra Energy”) (electricity-related services and renewable energy generator) in 2013, having served in that position since 2012. At NextEra Energy, he served as Chief Executive Officer from 2001 to 2012, Chairman from 2002 to 2012, and President from 2001 to 2006. He also served as Chief Executive Officer of Florida Power & Light Company from 2002 to 2008. Mr. Hay has served as a director of L3Harris Technologies, Inc. (global aerospace and defense technology firm) since June 2019 (and its predecessor company, Harris Corporation, from 2002 until June 2019) and Artera Services, LLC (provider of integrated infrastructure services to natural gas and electric industries) since August 2020 (and its predecessor company, PowerTeam Services, LLC, from 2018 until August 2020). Mr. Hay served as director of Capital One Financial Corporation (financial services) from 2013 until May 2019 and was a director and chairman of both the Institute of Nuclear Power Operations and the Edison Electric Institute until 2013. He also served on the Board of Business Advisors for the Tepper School of Business at Carnegie Mellon University and on the Advisory Council of Carnegie Mellon University’s Scott Institute for Energy Innovation until 2017. Director Qualifications Mr. Hay brings extensive CEO, finance and regulatory and public policy experience to the Board through his positions as CEO, Chairman and CFO of a large utility company which was subject to significant regulation and oversight. He also has environmental, social and governance experience with his management of the utility’s expansion of renewable energy sources. In addition, Mr. Hay has marketing and consumer insights experience from his service as an officer of a large utility company and a director of a financial services company, and technology experience from his service as a director of an information technology company. Mr. Hay qualifies as an “audit committee financial expert” under the rules of the Securities and Exchange Commission (“SEC”). | |
| Age: 53 Director Since: 2017 Committees: Audit Governance Skills, Experiences and Attributes • CEO • COO / Executive Leadership • Finance / Capital Markets • Marketing / Consumer Insights • Technology • Diversity | | | Antonio F. Neri Background Antonio F. Neri has been a director of the Company since December 2017. Mr. Neri has served as President and Chief Executive Officer of Hewlett Packard Enterprise Company (“Hewlett Packard Enterprise”) (technology company) since 2018. At Hewlett Packard Enterprise, he also served as President from 2017 to 2018 and Executive Vice President and General Manager, Enterprise Group from 2015 to 2017. Prior to Hewlett Packard Enterprise’s spinoff from HP Inc. (technology company), Mr. Neri held a variety of leadership roles at HP Inc. since 1995, including Senior Vice President and General Manager, Enterprise Group from 2014 to 2015, Senior Vice President and General Manager, HP Servers from 2013 to 2014 and Senior Vice President and General Manager, HP Technology Services from 2011 to 2013. Mr. Neri has served as a director of Hewlett Packard Enterprise since 2018. He was a director of H3C Technologies Co., LTD (information technology company), from 2016 to 2017. Director Qualifications Mr. Neri has significant technology and marketing and consumer insights experience, having held several leadership positions at firms that provide technology solutions to the business and public sectors, including his current position of President and CEO of a large, multinational enterprise information technology company. In addition, Mr. Neri brings CEO and finance experience to the Board gained through his positions with Hewlett Packard Enterprise. Mr. Neri qualifies as an “audit committee financial expert” under the SEC’s rules. | |
| Age: 65 Director Since: 2004 Committees: Compensation and Talent (Chair) Finance Skills, Experiences and Attributes • COO / Executive Leadership • Finance / Capital Markets • Technology • Diversity | | | Ramiro G. Peru Background Ramiro G. Peru has been a director of the Company since November 2004. Mr. Peru served on the former WellPoint Health Networks, Inc. board of directors from May 2003 until its merger with us in November 2004. During the second half of 2007, Mr. Peru was Executive Vice President and Chief Financial Officer of Swift Corporation (transportation) and prior thereto was Executive Vice President and Chief Financial Officer of Phelps Dodge Corporation (mining and manufacturing) from 1999 to 2007 (“Phelps Dodge”). Mr. Peru joined Phelps Dodge in 1979 and held various finance and accounting positions with Phelps Dodge and its affiliates. Mr. Peru has served as a director of SM Energy Company (oil and gas exploration and production company) since 2014, UNS Energy Corporation (electric and gas utility holding company), a subsidiary of Fortis Inc. (utility holding company), since 2007 and Bluemedia, Inc. (large format printer) since 2018. Director Qualifications Mr. Peru brings significant finance experience to the Board as a former chief financial officer of two public companies. Mr. Peru’s positions also included technology experience as Senior Vice President at Phelps Dodge with responsibility for managing both information systems and technology and human resources. | |
| 16 | | | | 2021 Proxy Statement | |
| Age: 59 Director Since: 2018 Committees: Compensation and Talent Governance Skills, Experiences and Attributes • CEO • COO / Executive Leadership • Finance / Capital Markets • Healthcare Industry • Diversity | | | Bahija Jallal Background Bahija Jallal has been a director of the Company since February 2018. Ms. Jallal has served as the Chief Executive Officer of Immunocore Limited (T cell receptor biotechnology company) since January 2019. Prior to that, she served as Executive Vice President of AstraZeneca PLC (“AstraZeneca”) (pharmaceutical and biopharmaceutical business) and President of MedImmune (biotechnology business), a subsidiary of AstraZeneca, since 2013. She joined MedImmune in 2006 and held various research and development positions, including Executive Vice President, Research and Development, from 2010 to 2013. Ms. Jallal has been a director of Immunocore Limited since January 2019 and Guardant Health, Inc. (precision oncology company) since April 2019. She is a member of the Board of Trustees of Johns Hopkins University, and a director of the University of Maryland Health Sciences Research Park Corporation. Ms. Jallal also served as director and past president of the Association for Women in Science from 2016 until 2018. Director Qualifications Ms. Jallal brings extensive healthcare industry experience to the Board gained through her several leadership positions at biopharmaceutical companies that provide new medicines to patients, including her current position of CEO at a multinational biotechnology company. In addition, Ms. Jallal has CEO and finance experience through her current position as CEO of a biotechnology company and her former position of President at a biologic research and development subsidiary of a large public company. | |
| Age: 51 Director Since: 2019 Committees: Compensation and Talent Finance Skills, Experiences and Attributes • CEO • COO / Executive Leadership • Insurance Industry • Finance / Capital Markets • Marketing / Consumer Insights • Technology • Regulatory / Public Policy | | | Ryan M. Schneider Background Ryan M. Schneider has been a director of the Company since October 2019. Mr. Schneider has served as the Chief Executive Officer and President of Realogy Holdings Corp. (“Realogy”) (residential real estate services) since December 2017 and previously served as President and Chief Operating Officer of Realogy from October 2017 to December 2017. Prior to that, Mr. Schneider was a Senior Advisor at McKinsey & Company (consulting firm) from May 2017 until October 2017. From 2001 to 2017, Mr. Schneider held various positions with Capital One Financial Corporation (financial services), including President, Card Business from 2007 until 2016 and Senior Advisor from 2016 until 2017. Mr. Schneider has served as a director of Realogy since 2017. He previously served as a director of Capital One Bank (USA) N.A. from 2007 to 2016. Director Qualifications Mr. Schneider brings significant CEO, COO, insurance industry, finance, marketing and consumer insights, and technology experience to the Board from his current chief executive officer and past leadership positions in real estate and financial services organizations. These positions also provided him with regulatory and public policy experience due to the highly-regulated nature of the banking industry. | |
| Age: 71 Director Since: 2013 Independent Chair of the Board Since: 2018 Committees: Audit Governance Skills, Experiences and Attributes • CEO • COO / Executive Leadership • Insurance Industry • Finance / Capital Markets • Healthcare Industry • Marketing / Consumer Insights • Regulatory / Public Policy • ESG • Diversity | | | Elizabeth E. Tallett Background Elizabeth E. Tallett has been a director of the Company since October 2013 and became independent Chair of the Board in May 2018. She was a principal of Hunter Partners, LLC (healthcare consulting) from 2002 to 2015. Ms. Tallett continues to operate as a consultant to healthcare companies. Previously, Ms. Tallett was President and Chief Executive Officer of Transcell Technologies, Inc. (specialty pharmaceuticals), President of Centocor Pharmaceuticals (biotechnology), member of the Parke-Davis (pharmaceuticals) Executive Committee and Director of Worldwide Strategic Planning for Warner-Lambert Company (pharmaceuticals). Ms. Tallett has served as a director of Meredith Corporation (media) since 2008, Qiagen, N.V. (molecular diagnostics and life sciences) since 2011 and Moderna, Inc. (biotechnology) since July 2020. Ms. Tallett has also served as a director of Principal Financial Group, Inc. (financial services) since 1992 (as lead director from 2007 until December 2019) and will be retiring from this board at its May 2021 annual shareholders meeting. She previously served as a director of Coventry Health Care, Inc. (health insurance) from 1998 to 2013 (including serving as lead director). Director Qualifications Ms. Tallett brings significant CEO, finance, healthcare industry, insurance industry and marketing and consumer insights experience to the Board from her chief executive, other management and board positions in several healthcare, insurance and pharmaceutical organizations. These positions also provided her with regulatory and public policy experience due to the highly-regulated nature of these organizations. She also has environmental, social and governance experience, having served as a lead director and as a member of the governance committees of several public companies. Ms. Tallett qualifies as an “audit committee financial expert” under the SEC’s rules. | |
| 18 | | | | 2021 Proxy Statement | |
| Age: 60 Director Since: 2017 Committees: None Skills, Experiences and Attributes • CEO • COO / Executive Leadership • Insurance Industry • Finance / Capital Markets • Healthcare Industry • Technology • Regulatory / Public Policy • Diversity | | | Gail K. Boudreaux Background Gail K. Boudreaux has been a director of the Company since November 2017 when she was appointed our President and Chief Executive Officer. Prior to joining the Company, she served as Chief Executive Officer of GKB Global Health, LLC (healthcare strategy and business advisory firm) from July 2015 to November 2017. Prior thereto, Ms. Boudreaux was Executive Vice President of UnitedHealth Group Incorporated (diversified healthcare company) from May 2008 to February 2015, including roles as President of United HealthCare (managed healthcare company), a subsidiary of UnitedHealth Group Incorporated, from May 2008 to January 2011 and Chief Executive Officer of United HealthCare from January 2011 to November 2014. Before joining United HealthCare, she worked at Health Care Services Corporation (“HCSC”) (health insurance company) as President of Blue Cross Blue Shield of Illinois from July 2002 to December 2005 and as Executive Vice President of External Operations from December 2005 to April 2008. Before joining HCSC, Ms. Boudreaux held various positions at Aetna Inc. (managed healthcare company), including Senior Vice President, Group Insurance. Ms. Boudreaux has served as a director of Zimmer Biomet Holdings, Inc. (medical device company) since 2012. She also serves as a director of the BCBSA, the National Institute for Health Care Management, Health Services Foundation, and the Central Indiana Corporate Partnership, and as a member of the Business Roundtable. She previously served as a director of Xcel Energy, Inc. (utility holding company) from 2012 to 2017, Novavax, Inc. (biotechnology company) from 2015 to 2017 and Genzyme Corporation (biotechnology company) from 2004 to 2011. Director Qualifications Ms. Boudreaux brings significant CEO, healthcare industry, insurance, finance and technology experience to the Board from her chief executive and other executive positions with several healthcare and insurance organizations and participation in numerous associations in the healthcare industry. Ms. Boudreaux’s positions also provided her with regulatory and public policy experience due to the highly-regulated nature of these organizations. She also gained financial and technology experience through her service as a director and as a member of the audit committee and technology operations committee of several public companies, including a medical device company and a biotechnology company. | |
| Age: 68 Director Since: 2014 Committees: Finance (Chair) Audit Skills, Experiences and Attributes • CEO • COO / Executive Leadership • Finance / Capital Markets • Healthcare Industry • Marketing / Consumer Insights • ESG | | | R. Kerry Clark Background R. Kerry Clark has been a director of the Company since May 2014. Mr. Clark served as Chairman and Chief Executive Officer of Cardinal Health, Inc. (healthcare products and services), until his retirement in 2009. Mr. Clark joined Cardinal Health, Inc. (“Cardinal Health”) in 2006 as President and Chief Executive Officer and became Chairman in 2007. Prior to joining Cardinal Health, he held various positions at The Procter & Gamble Company (consumer products), including President of P&G Asia; President, Global Market Development and Business Operations; and Vice Chairman of the Board, President Global Family Health. He has served as a director of General Mills, Inc. (consumer food products) since 2009 and Textron, Inc. (aircraft, defense and industrial products) since 2003. He previously served as a director of Avnet, Inc. (industrial distributors of electronic components, enterprise computer and storage products) from 2012 until November 2019. He is also a director of The Christ Hospital in Cincinnati, Ohio (hospital). Director Qualifications Mr. Clark brings to the Board extensive CEO, healthcare industry, marketing and consumer insights, and finance experience through his positions as Chairman and CEO of a major healthcare services organization, and as a senior executive at an international consumer products company, where he served in several positions involving marketing, advertising and product development of healthcare and other consumer products. Also, he has healthcare experience through his service on a hospital’s board of directors and environmental, social and governance experience through his roles as lead director and chair of the governance committee of a public company. Mr. Clark qualifies as an “audit committee financial expert” under the SEC’s rules. | |
| Age: 65 Director Since: 2011 Committees: Audit Finance Skills, Experiences and Attributes • COO / Executive Leadership • Marketing / Consumer Insights • Technology • ESG • Diversity | | | Robert L. Dixon, Jr. Background Robert L. Dixon, Jr. has been a director of the Company since July 2011. Mr. Dixon has been the owner of The RD Factor, Inc., a digital and information technology consulting business, since 2016. Prior thereto, he served as Global Chief Information Officer and Senior Vice President of PepsiCo, Inc. (“PepsiCo”) (food and beverages) from 2007 until April 2016 and as Senior Vice President until December 2016. Before joining PepsiCo, Mr. Dixon held various positions with The Procter & Gamble Company (consumer household products) since 1977, including Vice President of Global Business Services from 2005 until 2007. He has served as a director of Build-A-Bear Workshop, Inc. (specialty retailer) since 2018 and Okta, Inc. (identity management platform) since June 2019. At the Georgia Institute of Technology, Mr. Dixon serves on the President’s Advisory Board, the College of Computing Advisory Board and the Foundation. He previously served on the CIO Advisory Board for International Business Machines Corporation (a technology and consulting company). Director Qualifications Mr. Dixon has extensive technology experience through his position as Global Chief Information Officer of a large public company, his ownership of a digital and information technology consulting business, and his service on the CIO advisory board for another large public company. He also has significant marketing and consumer insights experience through his senior positions at two large public companies, both of which have global retail consumer product focus. Mr. Dixon has environmental, social and governance experience through his role as chair of the governance committee of a public company, as well as his several executive and academic board positions. | |
| 20 | | | | 2021 Proxy Statement | |
| Board | | ||||||||||||
| • Oversees management’s processes by which they identify, assess, monitor and manage the Company’s exposure to major risks to determine whether these processes are functioning as intended and are consistent with our business and strategy. | | ||||||||||||
| • Reviews certain risk tolerance levels and action plans regarding major risks. | | ||||||||||||
| • Reviews the Own Risk and Solvency Assessment Summary Report, which is filed annually with state insurance departments. | | ||||||||||||
| • Receives periodic reports from management on various risks, including risks facing our businesses or developments that could affect our risk profile. | | ||||||||||||
| • Delegates to its committees responsibility for assisting in the oversight of categories of risk within their areas of responsibility. | | ||||||||||||
| | | | | | | | | | | ||||
| | | | | | | | | | | ||||
| Audit Committee | | | | Compensation and Talent Committee | | | | Governance Committee | | | | Finance Committee | |
| • Receives quarterly reports from our Chief Risk Officer and reviews and discusses our enterprise risk management framework, processes and governance structure. • Reviews and approves the annual audit plan for our internal audit function, with a priority on areas based on their potential risk. • Reviews and discusses with management and the independent auditor our accounting, financial reporting and internal controls and procedures, our financial statements and the independent audit thereof. • Oversees our compliance activities and receives quarterly reports from our Chief Compliance Officer. • Reviews and discusses our major risks associated with our financials, strategy, information technology and security, compliance, privacy, ethics, litigation and reputation and other operational risks. • Regularly meets separately with representatives from our independent auditor, our Chief Risk Officer, our Chief Internal Audit Executive, our Chief Compliance Officer, our Chief Financial Officer and our Chief Legal Officer. | | | | • Oversees the risks associated with our compensation policies, practices and plans. • Reviews and discusses performance evaluations of the CEO and other executive officers. • Reviews and discusses talent acquisition and talent retention, including our inclusion and diversity efforts. | | | | • Oversees Board processes and corporate governance-related risks. • Monitors our corporate social responsibility and environmental sustainability initiatives and performance. • Reviews, at least annually, our political strategy, contributions and activities, and oversees compliance with our policies and procedures regarding political contributions and activities. | | | | • Oversees the risks associated with our capital structure, financial policies, financing strategies and financial condition. • Reviews the issuance and retirement of debt and other securities and our credit facilities. • Monitors investment and financial risk management strategies, including the use of derivatives. • Reviews proposed material mergers, acquisitions and divestitures. • Reviews our external insurance risk management program and insurance coverage. | |
| | | | | | | | | | | ||||
| | | | | | | | | | | ||||
| Management • Management, together with the Enterprise Risk Council, designs and implements processes by which they identify, assess, monitor and manage the Company’s exposure to major risks. | |
| |
| 22 | | | | 2021 Proxy Statement | |
| | | | | | | | | | | | | | |
| Our Consumers | | | | Our Communities | | | | Our Associates | | | | Our Environment | |
| Focus on care that delivers better health outcomes | | | | Focus on closing healthcare gaps in the diverse communities we serve | | | | Foster an inclusive and trusting environment where all associates have the opportunity to succeed | | | | Focus on the future well-being of the world around us | |
| | | | | | | | | | |
| | | | | | | | |||
| 60% of our healthcare spending in 2020 was in value-based care models | | | | Acquired Beacon Health, a behavioral health company, in 2020 | | | | Use of Live Health Online, our telehealth solution, and other telehealth services grew exponentially in 2020 | |
| | In response to the COVID-19 pandemic, we have taken numerous actions to help our consumers, including the following: • Waived all cost-sharing for COVID-19 diagnostic tests and treatment • Provided expanded telehealth coverage for our members and waived cost-sharing for in-network telehealth visits, including telephonic visits and those for mental health • Relaxed early prescription refill policies for maintenance and specialty medications • Provided a one-month premium credit to individuals and fully insured employer group customers enrolled in select Commercial and Specialty plans • Working with providers to accelerate claims processing, resolve claims, and accelerate payments to support state-specific Medicaid programs • Providing financial assistance to care provider partners facing undue financial pressure and to support ramping up telehealth capabilities and the cost of personal protective equipment (“PPE”) • Offered in-network dental providers a $10 PPE credit per patient, per visit • Suspended select prior authorization requirements • Partnering with our states in the distribution of COVID-19 vaccines • Launched the COVID-19 Vaccine tool to provide personalized vaccination insights for our members • Launched Sydney Care Daily COVID-19 Check-In to help employers and their employees quickly and safely return to work and make informed decisions about keeping their workforce safe • Analyzed vaccine availability, along with community demographic and consumer risk factor data, to support messages and intervention targeting consumers requiring priority focus • Pushed timely and relevant content to our consumers by our marketing teams to increase adoption of digital tools and encourage vaccination • Deployed Cl9 Explorer, a digital tool that aggregates real-time COVID-19 data to present trends and predictions for communities across the nation to assess readiness to reopen, plan next steps and respond to potential changes • Deployed Cl9 Navigator, a dashboard solution designed for Anthem employer customers to help inform workplace decisions and resource planning with employee-level data • Opened hundreds of digital solutions kiosks in health centers across California to provide real-time video interpretation services and access to telehealth • Deployed a Coronavirus Assessment tool within our Sydney Care app to help people quickly and safely evaluate symptoms, assess their risk of having COVID-19, and connect directly to a board-certified doctor via text or video • Introduced the Anthem Skill to members of our commercial medical and dental health plans. Through an Alexa-enabled device, members can use the Anthem Skill to take actions such as order prescriptions and quickly access some of their health and dental plan benefit information • Facilitating connections with Medicaid beneficiaries and state and social services, helping newly eligible and at risk members enroll in the Supplemental Nutrition Assistance Program (SNAP) and Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) • Conducted outreach to Medicare Advantage and Medicaid consumers to make sure they have necessary medications on hand, their nutritional needs are being met, and critical health needs are addressed • Recruited and expedited the onboarding of care providers interested in providing telehealth services to members • Provided resources to support the whole health needs of members, including resources to manage social isolation, job loss, food insecurity and stress | | |
| 24 | | | | 2021 Proxy Statement | |
| | | | | | | | | | |
| | | | | | | | |||
| $100 million pledged, with half to respond to COVID-19 and half to focus on social injustice and health inequities | | | | Over $45 million in active grants and sponsorships supporting over 500 nonprofit organizations | | | | Nearly 110,000 volunteer hours by our associates and $6.7 million donated through Associate Engagement Programs | |
| | In response to the COVID-19 pandemic, we have taken numerous actions to help our communities, including the following: • Committed $50 million from our Foundation for COVID-19 response and recovery efforts to help areas of greatest need, including care provider safety, food insecurity and behavioral health resources • Partnering with Lyft and others to provide transportation for at-risk communities to support universal access to the COVID-19 vaccine, with a goal of providing 60 million free rides • As communities across the country began to experience school closures, we provided $2 million to local Boys and Girls Clubs to help distribute meals to children and families who rely on school and Club meals and, at some Clubs, to support virtual programming to improve the physical and mental health of young people during this time • Partnered with New York City-based Coalition of Asian-American IPA, an independent practice association with over 1,000 private practice providers, to provide free mobile testing across New York City while increasing access to testing in many other markets across the U.S. • Through emergency relief funding to Americares and Direct Relief, our funding has enabled 38 million units of lifesaving PPE to get distributed to help safeguard frontline healthcare workers and protect the most vulnerable populations • In collaboration with Gleaners Food Bank, we are working to provide more than 10 million meals in our home city of Indianapolis by providing a $1 million matching grant to fight food insecurity and expand access to nutritious food • Collaborating with leading nonprofit partners and others to provide no-cost pop-up flu clinics in vulnerable communities across our markets to make it easier for people to get vaccinated and to increase health equity • Providing virtual volunteer opportunities, such as remote teaching or mailing cards to seniors facing loneliness, to help associates safely give back to communities • Anthem and our Foundation are founding anchor partners of XPRIZE Rapid COVID Testing, a collaboration with XPRIZE, OpenCovidScreen, and other Blue Cross and Blue Shield plans and innovative organizations to launch a $5 million competition to accelerate the development of high-quality COVID-19 testing that is low cost, easy to use and quick reporting, paving the way for more frequent testing • Managing a new study via our HealthCore subsidiary to help understand and combat Multisystem Inflammatory Syndrome in children, or MIS-C, arising from the COVID-19 pandemic • Anthem’s associates donated more than 25,000 pounds of food to food banks in communities across the country through virtual food drives and volunteered at more than 50 events as part of our Associate Volunteer Day • Launched the Pandemic Response Innovation Challenge with MATTER and Blue Cross and Blue Shield of Illinois to call on global innovators to develop creative solutions aimed at supporting the healthcare needs of those impacted by the COVID-19 pandemic | | |
| | | | | | | | | | |
| | | | | | | | |||
| Over 90% of our associates participated in monthly “Culture Conversations” | | | | Our managers are diverse, with 63% being women and 35% being ethnically diverse in the U.S. | | | | Over 11,500 associates participate in our nine associate resource groups | |
| 26 | | | | 2021 Proxy Statement | |
| | In response to the COVID-19 pandemic, we have taken numerous actions to help our associates, including the following: • Expanded associate benefits to provide additional support, including providing up to 80 hours of additional paid leave for COVID-19 related issues and offering virtual well-being resources • Deployed business continuity plans and transitioned nearly all associates to work from home while maintaining service levels and regular operations • Waived one month of premium costs for associates enrolled in an Anthem health plan • Created an online site for our associates to access all resources related to COVID-19 • Provided all associates with an extra paid day off as a “Wellness Holiday” • Provided resources and support to manage the complexities of working from home and handling caregiver and family needs • Ensuring our frontline medical staff are following CDC guidelines and are provided with the proper equipment and supplies to minimize risk to themselves and patients • Launched the confidential Associate CARE Service, a 24/7 hotline for emergencies such as food insecurity, childcare and caregiver needs and support for other needs | | |
| | | | | | | | | | |
| | | | | | | | |||
| Commitment to 100% renewable energy by 2025 | | | | Over 40% reduction of our scope I and II greenhouse gas intensity since baseline 2013, achieving our first generation target | | | | Over 50% of our real estate is certified under third party sustainability programs | |
| 28 | | | | 2021 Proxy Statement | |
| 30 | | | | 2021 Proxy Statement | |
| Directors | | | Audit Committee | | | Compensation and Talent Committee | | | Governance Committee | | | Finance Committee | |
| Gail K. Boudreaux | | | | | | | | | | | | | |
| R. Kerry Clark | | | | | | | | | | | Chair | | |
| Robert L. Dixon, Jr. | | | | | | | | | | | | ||
| Lewis Hay, III | | | Chair | | | | | | | | | | |
| Julie A. Hill | | | | | | | | Chair | | | | | |
| Bahija Jallal | | | | | | | | | | | | ||
| Antonio F. Neri | | | | | | | | | | | | ||
| Ramiro G. Peru | | | | | | Chair | | | | | | | |
| Ryan M. Schneider | | | | | | | | | | | | ||
| Elizabeth E. Tallett | | | | | | | | | | | |
| | | |||
| Audit Committee | | |||
| Principal Responsibilities: • The Audit Committee represents and assists the Board in its oversight of our accounting, financial reporting and internal controls over financial reporting. • In its oversight of our financial statements and the independent audit thereof, the Audit Committee is responsible for the selection, evaluation and, where deemed appropriate, replacement of the independent registered public accounting firm, and for the evaluation of the independence of the independent registered public accounting firm. • The Audit Committee is directly involved in the selection of the auditor’s lead engagement partner. • The Audit Committee is also responsible for the oversight of our compliance program and Code of Conduct, as well as assisting the Board in overseeing the processes by which we identify, assess, monitor and manage our exposure to major risks. The Chief Compliance Officer facilitates our compliance program and reports independently to the Audit Committee. The Audit Committee regularly receives a detailed report from the Chief Compliance Officer regarding our compliance program activities. See “Audit Committee Matters — Audit Committee Report” and “Corporate Governance — The Board’s Role and Responsibilities — Board Role in Risk Oversight.” The Audit Committee met separately at several meetings during 2020 with executive management (including the Chief Financial Officer and the Chief Legal Officer), the Chief Internal Audit Executive, the Chief Risk Officer, the Chief Compliance Officer and the independent registered public accounting firm. The Board has determined that each of the members of the Audit Committee is “independent” as defined by the rules of the SEC and the NYSE listing standards. The Board has determined that, with the exception of Mr. Dixon, each of the Audit Committee members is an “audit committee financial expert” as defined by the SEC’s rules. | | |||
| Lewis Hay, III – Chair Members: R. Kerry Clark Robert L. Dixon, Jr. Antonio F. Neri Elizabeth E. Tallett Meetings in 2020: 8 | |
| | | |||
| Compensation and Talent Committee | | |||
| Principal Responsibilities: • The Compensation and Talent Committee assists the Board in discharging its responsibilities relating to compensation and benefits provided to our executive officers (which are determined by the Compensation and Talent Committee in its sole discretion), including overseeing an assessment of the risks related to our compensation policies and practices. See “Corporate Governance — The Board’s Role and Responsibilities — Board Role in Risk Oversight — Assessment of Compensation-Related Risks.” • The Compensation and Talent Committee sets the compensation level of our CEO and other executive officers based on an evaluation of the executive’s performance in light of our goals and objectives. • The Compensation and Talent Committee may take into consideration when setting the compensation levels of the executive officers (other than the CEO) any recommendations of the CEO with respect to the other executive officers. • In addition, the Compensation and Talent Committee has directly engaged Semler Brossy Consulting Group LLC (“Semler Brossy”), an outside compensation consultant, to assist in the evaluation of CEO and executive officer compensation, as authorized under its charter. Semler Brossy reports directly to the Compensation and Talent Committee, participates regularly in Compensation and Talent Committee meetings and advises the Compensation and Talent Committee with respect to compensation trends and best practices, plan design and the reasonableness of individual compensation awards. Semler Brossy does not provide any other services to the Company. The Compensation and Talent Committee assessed the independence of Semler Brossy pursuant to, and based on the factors set forth in, the SEC’s and NYSE’s rules and concluded that no conflict of interest exists that would prevent Semler Brossy from independently advising the Compensation and Talent Committee. • The Compensation and Talent Committee reviews and discusses talent acquisition and talent retention, and also monitors our programs and practices related to workforce diversity and inclusion. All members of the Compensation and Talent Committee are “non-employee directors” within the meaning of Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and “independent” within the meaning of the NYSE listing standards. None of the Compensation and Talent Committee members is or has been an officer or employee of the Company or was involved in a relationship requiring disclosure as an interlocking director or under Item 404 of Regulation S-K. | | |||
| Ramiro G. Peru – Chair Members: Julie A. Hill Bahija Jallal Ryan M. Schneider Meetings in 2020: 5 | |
| 32 | | | | 2021 Proxy Statement | |
| | | |||
| Governance Committee | | |||
| Principal Responsibilities: • The Governance Committee assists the Board in discharging its responsibilities relating to Board composition and evaluations, non-employee director compensation and corporate governance by identifying and recommending individuals for nomination as members of the Board, recommending to the Board the overall non-employee director compensation policy and developing and recommending to the Board a set of corporate governance guidelines. • The Governance Committee also is responsible for reviewing, at least annually, our political strategy, contributions and activities, including our Annual Report on Political Contributions and Related Activities, and overseeing compliance with our policies and procedures regarding political contributions and activities. • In addition, the Governance Committee monitors our corporate social responsibility and environmental sustainability initiatives, including our Corporate Responsibility Report, which is prepared in accordance with the GRI Core Reporting Guidelines and includes SASB metrics. • The Governance Committee has directly engaged Compensation Advisory Partners LLC (“CAP”), an outside compensation consultant, to assist in the evaluation of director compensation, as authorized under its charter. CAP reports directly to the Governance Committee. During 2020, CAP advised the Governance Committee with respect to director compensation trends and best practices, plan design and the reasonableness of director compensation. CAP does not provide any other services to the Company. The Governance Committee assessed the independence of CAP pursuant to, and based on the factors set forth in, the SEC’s and NYSE’s rules and concluded that no conflict of interest exists that would prevent CAP from independently advising the Governance Committee. The Board has determined that each of the members of the Governance Committee is “independent” as defined by the NYSE listing standards. | | |||
| Julie A. Hill – Chair Members: Bahija Jallal Antonio F. Neri Elizabeth E. Tallett Meetings in 2020: 4 | |
| | | |||
| Finance Committee | | |||
| Principal Responsibilities: • The Finance Committee assists the Board in fulfilling its responsibilities related to our capital structure, financial policies, financing strategies and financial condition. • The Finance Committee is responsible for approving our annual capital plan and reviewing the issuance and retirement of debt and other securities and our credit facilities, as well as reviewing investment and financial risk management strategies. • The Finance Committee provides guidance to the Board on significant policies and matters of financial corporate governance, including our use of capital, dividend policy, share repurchase program and credit ratings. • The Finance Committee reviews our external insurance risk management program and insurance coverage. • The Finance Committee also reviews proposed material mergers, acquisitions and divestitures. The Board has determined that each of the members of the Finance Committee is “independent” as defined by the NYSE listing standards. | | |||
| R. Kerry Clark – Chair Members: Robert L. Dixon, Jr. Lewis Hay, III Ramiro G. Peru Ryan M. Schneider Meetings in 2020: 5 | |
| Board Independence | | | • Independent Chair of the Board • Nine out of ten directors are independent • Only independent directors serve on the Audit, Compensation and Talent, Governance and Finance Committees | |
| Board Diversity | | | • Four out of ten directors are women • Seven out of ten directors are gender and/or ethnically diverse • Balanced director tenure, with the average tenure being approximately 7.6 years • Board composition is also diverse in age, geographic location, skills and experiences | |
| Shareholder Rights | | | • Proxy access for shareholder-nominated director nominees • Majority voting for uncontested director elections, with directors who fail to receive a majority vote required to tender their resignation for consideration by the Board • No supermajority voting requirements in our Articles of Incorporation • Opted out of the Indiana Control Share Acquisition Statute • Shareholders have the right to call a special meeting of shareholders • Shareholders can amend our Bylaws, except for those provisions required by our licenses with the BCBSA • Long-standing practice of shareholder engagement on governance, compensation and sustainability issues | |
| Other Leading Governance Practices | | | • Annual Board, committee and individual director performance evaluations, including evaluations led by an external party • Board oversees director refreshment and succession planning and executive officer succession planning, addressing both emergency and long-term succession • Directors are not eligible for election if 72 years of age or older • Directors may generally serve on no more than three other public company boards; however, the Board granted an exception for Ms. Tallett to join the board of Moderna, Inc., temporarily bringing her total other public company board service to four until her planned retirement from another public company board in May 2021 • Our CEO may serve on no more than one other public company board • Rotation of lead partner of our independent registered public accounting firm at least every five years • The Board and its committees have the authority to engage consultants and advisors at our expense • Executive sessions of independent directors are generally held at each regularly scheduled Board meeting • Strong compensation governance practices as discussed in the Compensation Discussion & Analysis • Board and committee oversight of risk, including risks relating to financial reporting, compensation practices and cybersecurity • The Board encourages directors to participate in continuing education programs and reimburses directors for the expense of such participation • Several avenues for shareholders to communicate with the Board and management, including periodic investor days, earnings release conference calls and a dedicated email address for the Board | |
| 34 | | | | 2021 Proxy Statement | |
| Governance Documents at www.antheminc.com | | | • Articles of Incorporation • Bylaws • Corporate Governance Guidelines • Standards of Director Independence • Code of Conduct • Insider Trading Policy • Board Committee Charters • Annual Report on Political Contributions and Related Activities | |
| Solicitation | | | Board, committee and individual director performance evaluations: • Board evaluation is facilitated by the Chair of the Governance Committee and an external party • Individual director assessments are facilitated by an external party • Committee evaluations are conducted for each of the committees upon which directors serve | |
| Evaluation and Assessment | | | Directors provide feedback regarding the Board, committees and peers: • Evaluation of Board membership • Exploration of Board member behaviors as compared to those of effective boards • Assessment of meetings, materials and Board deliberations • Examinations of key functions, including those that maximize shareholder value | |
| Board Review | | | • Summary of Board and committee evaluations, in addition to individual director feedback, provided to the Board • Chairs of each of the committees lead a discussion of committee evaluation results • External party communicates the results of the individual director assessments to the Board, as well as the individual directors | |
| Incorporation of Feedback | | | • Follow-up items are addressed at subsequent Board or committee meetings • As appropriate, Board and committee action plans are prepared to address issues | |
| Compensation Element | | | 2020 | | |||
| Annual Retainer – Cash Portion | | | | $ | 125,000 | | |
| Annual Retainer – Company Stock Portion | | | | $ | 195,000 | | |
| Annual Committee Chair Retainers | | | | | | | |
| • Audit Committee | | | | $ | 30,000 | | |
| • Compensation and Talent, Governance and Finance Committees | | | | $ | 20,000 | | |
| Annual Retainer for Non-Executive Chair of the Board, if any | | | | $ | 240,000 | | |
| Annual Retainer for Lead Director, if any | | | | $ | 35,000 | | |
| 36 | | | | 2021 Proxy Statement | |
| Name | | | Fees Earned or Paid in Cash ($)(1) | | | Stock Awards ($)(2) | | | All Other Compensation ($)(3) | | | Total ($) | | ||||||||||||
| R. Kerry Clark | | | | $ | 137,480 | | | | | $ | 194,797 | | | | | $ | 10,000 | | | | | $ | 342,277 | | |
| Robert L. Dixon, Jr. | | | | $ | 125,203 | | | | | $ | 194,797 | | | | | $ | 25,786 | | | | | $ | 345,786 | | |
| Lewis Hay, III | | | | $ | 145,203 | | | | | $ | 194,797 | | | | | $ | 5,000 | | | | | $ | 345,000 | | |
| Julie A. Hill | | | | $ | 145,203 | | | | | $ | 194,797 | | | | | $ | 25,786 | | | | | $ | 365,786 | | |
| Bahija Jallal | | | | $ | 125,203(4) | | | | | $ | 194,797 | | | | | | — | | | | | $ | 320,000 | | |
| Antonio F. Neri | | | | $ | 125,203 | | | | | $ | 194,797 | | | | | $ | 5,000 | | | | | $ | 325,000 | | |
| Ramiro G. Peru | | | | $ | 155,203 | | | | | $ | 194,797 | | | | | $ | 15,786 | | | | | $ | 365,786 | | |
| Ryan M. Schneider | | | | $ | 125,203 | | | | | $ | 194,797 | | | | | | — | | | | | $ | 320,000 | | |
| Elizabeth E. Tallett | | | | $ | 365,203(4) | | | | | $ | 194,797 | | | | | $ | 10,000 | | | | | $ | 570,000 | | |
| Director | | | Deferred Shares (as of 12/31/20) | | |||
| R. Kerry Clark | | | | | 7,261 | | |
| Robert L. Dixon, Jr. | | | | | 4,503 | | |
| Lewis Hay, III | | | | | 9,128 | | |
| Julie A. Hill | | | | | 32,521 | | |
| Bahija Jallal | | | | | 2,409 | | |
| Antonio F. Neri | | | | | 2,546 | | |
| Ramiro G. Peru | | | | | 4,503 | | |
| Ryan M. Schneider | | | | | 1,221 | | |
| Elizabeth E. Tallett | | | | | 8,513 | | |
| 38 | | | | 2021 Proxy Statement | |
| Name and Position | | | Age | | | | |
| Gail K. Boudreaux President and Chief Executive Officer | | | 60 | | | See the biographical information under “Directors Continuing in Office — Terms Expiring at the 2023 Annual Meeting of Shareholders” on page 19. | |
| Jeffrey D. Alter EVP, IngenioRx and Anthem Health Solutions | | | 58 | | | Mr. Alter has served as our Executive Vice President, IngenioRx and Anthem Health Solutions since September 2020. Prior to joining us, Mr. Alter was President (and Founder) of ArcturusOne Consulting, LLC (healthcare consulting) from July 2018 to September 2020. Prior to that, Mr. Alter spent 14 years at United HealthCare (managed healthcare company) in various roles, including as Chief Executive Officer of its Commercial Group from November 2014 until June 2018. Mr. Alter also served as Senior Vice President of Strategic Financial Planning for Oxford Health Plans, Inc. (health insurance) from December 2002 to April 2004. | |
| John E. Gallina EVP and Chief Financial Officer | | | 61 | | | Mr. Gallina has served as our Executive Vice President and Chief Financial Officer since June 2016. Mr. Gallina joined Anthem in 1994 and has held a variety of leadership roles across the organization. Prior to his current role, Mr. Gallina served as Anthem’s Chief Financial Officer for the Commercial and Specialty Business Division from December 2015 to June 2016, and as Senior Vice President and Chief Accounting Officer from December 2013 to December 2015. Other leadership positions held during his tenure include Senior Vice President, Chief Accounting Officer and Chief Risk Officer from May 2011 to December 2013, while also holding the title of Controller from May 2011 to August 2013. Before joining the Company, Mr. Gallina spent 12 years with Coopers & Lybrand in various positions, including as an Audit Senior Manager. | |
| Peter D. Haytaian EVP and President, Commercial and Specialty Business Division | | | 51 | | | Mr. Haytaian has served as our Executive Vice President and President of the Commercial and Specialty Business Division since March 2018. From June 2014 until March 2018, Mr. Haytaian served as our Executive Vice President and President of the Government Business Division. Mr. Haytaian joined the Company in December 2012 with our acquisition of Amerigroup Corporation (“Amerigroup”) and served as President of our Medicaid business from August 2013 until June 2014. From 2005 to 2013, Mr. Haytaian held several leadership positions with Amerigroup, including serving as Chief Executive Officer of the North Region for Amerigroup’s Medicaid business from December 2012 until August 2013. Mr. Haytaian has extensive experience leading Medicare and Medicaid programs with Amerigroup and, prior thereto, with Oxford Health Plans, Inc. | |
| Gloria M. McCarthy EVP and Chief Administrative Officer | | | 68 | | | Ms. McCarthy has served as our Executive Vice President and Chief Administrative Officer since 2013. She was Executive Vice President of Enterprise Execution and Efficiency from 2012 to 2013. Prior to that appointment, she served as Executive Vice President, Office of the CEO from February 2012 to October 2012, as Senior Vice President for Operational Excellence from 2008 to February 2012, as Senior Vice President of Service Operations from 2006 to 2008 and as Senior Vice President and Chief Operating Officer of our East Region from 2005 to 2006. Prior to our acquisition of WellChoice, Inc. (“WellChoice”) in 2005, Ms. McCarthy served as Executive Vice President and Chief Operating Officer of WellChoice. | |
| Felicia F. Norwood EVP and President, Government Business Division | | | 61 | | | Ms. Norwood has served as our Executive Vice President and President of the Government Business Division since June 2018. Prior to joining us, she was Director of The Department of Healthcare and Family Services for the State of Illinois from January 2015 to June 2018. Prior to that appointment, Ms. Norwood served as President of the Mid-America Region for Aetna Inc. (health insurance) from January 2010 until May 2013. | |
| Name and Position | | | Age | | | | |
| Prakash Patel, M.D. EVP and President, Diversified Business Group | | | 54 | | | Dr. Patel has served as our Executive Vice President and President, Diversified Business Group since August 2018. Prior to joining us, Dr. Patel was Chief Operating Officer and President, GuideWell Health for GuideWell Mutual Holding Corporation (not-for-profit mutual holding company) from January 2015 to August 2018. Prior to that, Dr. Patel was Chief Executive Officer of Access MediQuip (provider of surgical implant management solutions) from January 2011 to November 2014. From April 2005 to December 2010, Dr. Patel held various positions with Magellan Health Services (healthcare services), the most recent being Chief Corporate Development Officer. | |
| Leah Stark EVP and Chief Human Resources Officer | | | 44 | | | Ms. Stark has served as our Executive Vice President and Chief Human Resources Officer since January 2019. From July 2016 to June 2018, she held the position of Chief Human Resources Officer and Head of Procurement of General Cable Corporation (telecom cable systems company). Prior to that, beginning in March 2006, Ms. Stark held a variety of leadership roles at Whirlpool Corporation (home appliance company), with her most recent roles as Senior Director, Global Human Resources from August 2015 until July 2016 and as Head of Human Resources, North Asia & Whirlpool China Co. Ltd from November 2013 until August 2015. | |
| Blair W. Todt EVP and Chief Legal Officer | | | 53 | | | Mr. Todt has served as our Executive Vice President and Chief Legal Officer since November 2020. Prior to joining us, Mr. Todt served as Senior Vice President, Legal, Compliance & Business Performance and Chief Legal Officer of HCSC from July 2016 to July 2020. Prior to joining HCSC, Mr. Todt held a variety of leadership roles at WellCare Health Plans, Inc. (health insurance company), with his most recent role as Senior Vice President, Chief Legal and Administrative Officer and Secretary from April 2010 until June 2016. | |
| Ronald W. Penczek SVP and Chief Accounting Officer | | | 56 | | | Mr. Penczek has served as our Senior Vice President and Controller since November 2015 and as our Chief Accounting Officer since December 2015. He served as our Vice President and Controller from August 2013 to November 2015. Prior to that appointment, Mr. Penczek served as Vice President and Assistant Controller from January 2008 to August 2013 and in various other roles in our finance department from February 2006 until January 2008. Before joining us, Mr. Penczek was a Staff Vice President with CNA Insurance from 2000 to 2005 and held various positions with PricewaterhouseCoopers LLP from 1992 to 2000, including as a Manager. | |
| 40 | | | | 2021 Proxy Statement | |
| PROPOSAL 2 | |
| Advisory Vote to Approve the Compensation of Our Named Executive Officers | |
| | | |||
| | | The Board of Directors unanimously recommends a vote FOR Proposal 2, the advisory vote to approve the compensation of our Named Executive Officers. | |
| | | | | | | | | | |
| | | | | | | | |||
| Our programs are intended to be generally consistent in design and in aggregate size with market and good corporate governance practices | | | | We consider both external competitiveness and internal equity in the operation and administration of these programs | | | | These objectives are extended beyond the executive ranks to include all associates and are intended to promote the Company’s culture, as well as enhance teamwork and equitable treatment | |
| 42 | | | | 2021 Proxy Statement | |
| Our Purpose | |
| Improving the Health of Humanity. | |
| Our Mission | |
| Improving Lives and Communities. Simplifying Healthcare. Expecting More. | |
| Our Vision | |
| Be the most innovative, valuable and inclusive partner. | |
| Our Values | | ||||||||||||
| Leadership Redefine what’s possible. | | | Community Committed, connected, invested. | | | Integrity Do the right thing, with a spirit of excellence. | | | Agility Deliver today — transform tomorrow. | | | Diversity Open your hearts and minds. | |
| Total Operating Revenue ($ in billions) | | | Net Income Per Diluted Share | | | Adjusted Net Income Per Diluted Share* | |
| | | | | |
| | COVID-19 Impact on Our Compensation Programs | | |
| | Compensation decisions for our NEOs for 2020, including annual base salaries and performance metrics, weightings and targets for our 2020 AIP and our 2020-2022 performance stock units (“PSUs”), were made in February 2020 prior to COVID-19 being declared a pandemic. Performance was monitored throughout the year, and no structural changes were made to the approved compensation actions or the weightings and metrics of our outstanding incentive programs due to the COVID-19 pandemic. | | |
| | As a result of the unique challenges our customers and communities faced during the COVID-19 pandemic, our management made decisions to proactively provide over $2.5 billion in direct support and assistance to our customers, care providers, associates and nonprofit partners during this difficult time. These decisions were intentional and were done for the betterment of our members and communities and a portion were in addition to the mandated actions required as a result of the CARES Act and other mandates. After review of these decisions and their impact to our earnings and our revenue, the Committee made adjustments for a portion of the voluntary actions taken when calculating the amounts earned under the 2020 AIP and the 2018-2020 PSU awards so that they more appropriately reflected management’s performance for 2020. These adjustments exclude the financial impact of the voluntary actions listed below: • Provided a one-month premium credit to individuals and fully insured employer group customers enrolled in select Commercial and Specialty plans • Offered in-network dental providers a $10 PPE credit per patient, per visit • Provided expanded telehealth coverage for our members and waived cost-sharing for in-network telehealth visits, including telephonic visits, and those for mental health | | |
| | Over the course of 2020, our management, the Committee and the Committee’s independent compensation consultant explored potential 2021 long-term incentive approaches, recognizing the inherent challenge in setting long-term goals in this environment. After a thorough review, there are no planned changes to our compensation programs for 2021 related to the COVID-19 pandemic. | | |
| What We Do | |
| Rigorous establishment and oversight of incentive measures, goals and pay / performance relationship | |
| Align executive compensation with shareholder returns through a mix of variable and fixed compensation that is heavily weighted toward variable, long-term performance- based compensation, with caps on AIP and PSU payouts | |
| Significant director and executive stock ownership requirements and holding restrictions | |
| Clawback policy for executive officers’ incentive compensation, including for reputational harm | |
| Double-trigger change-in-control provisions | |
| No dividends paid on stock units until they vest | |
| Limited executive perquisites | |
| What We Do Not Do | | |||
| | | No backdating, re-pricing, discounting, reloading or replacing of stock options or stock appreciation rights without shareholder approval | | |
| | | No change-in-control excise tax gross-ups | | |
| | | No short sales, hedging or pledging of our stock is permitted by any director or associate, including our executive officers | | |
| | | No compensation plans which encourage excessive risk taking | | |
| | | |
| 44 | | | | 2021 Proxy Statement | |
| Annual Incentive Plan | | | • Changed the financial performance measure from Operating Gain to Operating Revenue and Adjusted Net Income to focus on continued top-line growth • Increased the aggregate weighting of non-financial measures to 30% to ensure appropriate focus on our strategic goals • Increased the difficulty to achieve threshold performance and adjusted the payout for meeting threshold to 30% • Metrics for the relative peer modifier changed from Operating Gain and Total Revenue growth to Adjusted Net Income growth and Total Revenue growth for consistent measurement among our peers See page 50 | |
| Long-Term Incentive Plan Awards – PSUs | | | • Increased the weighting of Operating Revenue from 25% to 40% to increase focus on top-line growth See page 55 | |
| Compensation Decision Making Process and Key Considerations | | ||||||||||||||||||||
| | |||||||||||||||||||||
| | |||||||||||||||||||||
| | |||||||||||||||||||||
| A Unified Approach to Bring Together Both External and Internal Resources to Make Well-Informed Compensation Decisions | | ||||||||||||||||||||
| | |||||||||||||||||||||
| | | | | | | | | | | | | | | | | ||||||
| | | | | | | | | | | | | | | | | ||||||
| The Role of the Committee | | | | Shareholder Outreach and Say-on-Pay Votes | | | | The Role of the Independent Compensation Consultant | | | | Market Assessment and Peer Practices | | | | Internal Comparisons and the Use of Tally Sheets | | | | The Role of Management | |
| 46 | | | | 2021 Proxy Statement | |
| Measure | | | Median of General Industry Group | | | Anthem | | | Percent of Median | | ||||||
| 3-Year Average EBIT (Earnings Before Interest and Taxes) | | | | $ | 5,582 | | | | | $ | 5,605 | | | | 100% | |
| Market Capitalization | | | | $ | 71,072 | | | | | $ | 73,578 | | | | 104% | |
| Primary Components | | | Strategic Purpose | |
| Base Salary | | | • Fixed annual compensation designed to attract and retain key talent • Set with reference to scope of responsibility, experience, individual performance and the competitive market Page 49 | |
| Annual Incentive Plan | | | • Performance-based and therefore variable cash compensation designed to reward achievement of short-term business objectives • Measures align to interests of shareholders to optimize profitability and include both financial and non-financial performance measures • Awards may be adjusted, either up or down, to reflect individual performance Page 50 | |
| Long-Term Incentive Plan Awards | | | • PSUs, which are performance-based and are earned over a three-year performance period • Stock options that provide value with sustained stock price appreciation over the grant term • Restricted stock units (“RSUs”) that time vest and provide both retention and stock price appreciation incentives Page 53 | |
| Broad-Based Benefits | | | • Participation in the same basic health and welfare benefits as other associates, although more highly paid associates, including NEOs, have a higher associate contribution (i.e., they pay more for their medical benefits than lower paid associates) • Benefits are focused on promoting the health, well-being and financial security of all associates, including the NEOs Page 57 | |
| Executive Benefits and Perquisites | | | • Limited perquisites and executive benefits that are market competitive • Designed to attract and retain key talent Page 58 | |
| 48 | | | | 2021 Proxy Statement | |
| CEO | | | Other NEOs | |
| | | |
| Name | | | 2019 Base Salary | | | | 2020 Base Salary | | | | % of Increase | | ||||||
| Gail K. Boudreaux | | | | $ | 1,400,000 | | | | | | $ | 1,400,000 | | | | | 0% | |
| John E. Gallina | | | | $ | 825,000 | | | | | | $ | 850,000 | | | | | 3.0% | |
| Peter D. Haytaian | | | | $ | 825,000 | | | | | | $ | 850,000 | | | | | 3.0% | |
| Gloria M. McCarthy | | | | $ | 825,000 | | | | | | $ | 850,000 | | | | | 3.0% | |
| Felicia F. Norwood | | | | $ | 725,000 | | | | | | $ | 800,000 | | | | | 10.3% | |
| Base Salary (Eligible Earnings) | | | | | Target Incentive Percent | | | | | Enterprise Performance Dashboard Results as a % of Target | | | | | Relative Peer Modifier | | |||
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | ||||
| | |||||||||||||||||||
| Individual Performance Modifier | |
| 50 | | | | 2021 Proxy Statement | |
| Performance Measure | | | Weighting | | | Criteria and Strategic Importance | |
| Adjusted Net Income Our primary profitability metric with focus on Company financial performance | | | | | • Adjusted Net Income is used by management to evaluate our core operating results and is reported to our shareholders on a quarterly basis so they can understand and analyze our core operating results and compare them among performance periods • Adjusted Net Income incorporates below-the-line performance, while excluding the impact of share count, which the Committee believes provides a more accurate measure of Company earnings against which to measure our growth for incentive purposes • Target based on 12.8% growth across our business | | |
| Operating Revenue Our primary financial growth metric | | | | | • Operating Revenue is a key measure used by management to evaluate growth in each of our reporting segments and is reported to our shareholders on a quarterly basis so they can understand and analyze our core operating results and compare them among performance periods • Successful top-line growth is a key component of our long-term growth plan • Target based on 13.4% growth across our business | | |
| Provider Collaboration Focus on our relationship with providers | | | | | • Increase the percentage of members with affinity to a high-performing primary care provider to ensure strong cost and quality performance by providers • Target based on a 150 basis point increase year-over-year in the percentage of membership tied to high-performing providers | | |
| Star Ratings Focus on achieving Medicare goals that most significantly improve clinical outcomes | | | | | • Increase the percentage of Medicare members in 4-STAR or better plans, which will have a direct impact on Medicare revenue in 2022 • Target represents substantially meaningful improvement over prior year performance | | |
| Consumer Effort Focus on the Consumer Experience | | | | | • Measures the overall sentiment of our members about how easy their health insurance company is to do business with • Target represents substantially meaningful improvement over prior year performance | | |
| Total | | | 100% | | | | |
| Performance Measure | | | | Target Performance | | | | Actual 2020 Performance | |
| Adjusted Net Income | | | | $5,709 million | | | | $5,984 million(1) Exceeded Target | |
| Operating Revenue | | | | $117,000 million | | | | $118,060 million(1) Exceeded Target | |
| Provider Collaboration | | | | 40.0% | | | | 41% Exceeded Target | |
| Star Ratings | | | | Substantially meaningful improvement over 2019 performance | | | | Missed Threshold | |
| Consumer Effort | | | | Substantially meaningful improvement over 2019 performance | | | | Missed Target | |
| Name | | | Target AIP % | | | Target Award | | | Final Award | | | Final Payout as % of Target | | ||||||
| Gail K. Boudreaux | | | 186%(1) | | | | $ | 2,600,000 | | | | | $ | 3,270,800 | | | | 125.8% | |
| John E. Gallina | | | 100% | | | | $ | 845,192 | | | | | $ | 1,183,269 | | | | 140.0% | |
| Peter D. Haytaian | | | 100% | | | | $ | 845,192 | | | | | $ | 1,183,269 | | | | 140.0% | |
| Gloria M. McCarthy | | | 100% | | | | $ | 845,192 | | | | | $ | 1,183,269 | | | | 140.0% | |
| Felicia F. Norwood | | | 100% | | | | $ | 785,577 | | | | | $ | 1,099,808 | | | | 140.0% | |
| 52 | | | | 2021 Proxy Statement | |
| Award Type | | | Weighting | | | Key Features and Performance Measures | |
| Performance Stock Units Focus on sustained performance and profitable growth | | | | | • Opportunity to earn from 0% to 200% of target PSUs based on achievement of pre-established three-year (2020-2022) cumulative Adjusted Net Income (weighted 60%) and cumulative Operating Revenue (weighted 40%) • Threshold, target and maximum performance goals are anchored on the Company’s long-term strategic plan and are critically important for driving long-term success by rewarding both top-line and bottom-line growth • Cash dividend equivalents accrue during the vesting period but are only paid when the underlying PSUs vest and are distributed. Dividend equivalents are cancelled if the underlying units do not vest • Actual payout level to be determined by the Committee following completion of the 2020-2022 performance period | | |
| Stock Options Focus on sustained stock price appreciation | | | | | • Provide intended value only when our stock price substantially increases over the exercise price (closing price of our common stock on pre-established grant date) • Have a term of 10 years • Vest in three equal annual installments, beginning on the first anniversary of the grant date | | |
| Restricted Stock Units Focus on stock value and executive retention | | | | | • Enables executive to build levels of stock ownership • Vest in three equal annual installments, beginning on the first anniversary of the grant date • Cash dividend equivalents accrue during the vesting period but are only paid when the underlying RSUs vest and are distributed. Dividend equivalents are cancelled if the underlying units do not vest | |
| Name | | | 2020-2022 PSU Target Award Grant Date Fair Value | | | Annual Stock Options Grant Date Fair Value | | | Annual RSU Grant Date Fair Value | | | Total 2020 LTIP Granted | | ||||||||||||
| Gail K. Boudreaux | | | | $ | 5,999,950 | | | | | $ | 2,999,847 | | | | | $ | 3,000,246 | | | | | $ | 12,000,043 | | |
| John E. Gallina | | | | $ | 1,624,907 | | | | | $ | 812,385 | | | | | $ | 812,725 | | | | | $ | 3,250,017 | | |
| Peter D. Haytaian | | | | $ | 1,624,907 | | | | | $ | 812,385 | | | | | $ | 812,725 | | | | | $ | 3,250,017 | | |
| Gloria M. McCarthy | | | | $ | 1,624,907 | | | | | $ | 812,385 | | | | | $ | 812,725 | | | | | $ | 3,250,017 | | |
| Felicia F. Norwood | | | | $ | 1,624,907 | | | | | $ | 812,385 | | | | | $ | 812,725 | | | | | $ | 3,250,017 | | |
| 54 | | | | 2021 Proxy Statement | |
| Performance Period | | | 2018 | | | 2019 | | | 2020 | | | 2021 | | | 2022 | |
| | | | 2018-2020 50% of LTIP Award • Risk and reward profile was modified to align with results of our multi-year Business Optimization initiative, with the payout for achieving target performance against baseline performance goals set at 75% • Opportunity to earn from 0% to 400% of target award: up to 150% based on three-year cumulative Adjusted Net Income (75% weighting) and Operating Revenue (25%), with up to an additional 250% for achievement of significant Business Optimization results • Established an Adjusted Net Income performance gate, as maximum performance on Adjusted Net Income baseline goals must be achieved before any incremental Business Optimization opportunity is available | | | | | | | | ||||||
| Performance Measures and Award Opportunity | | | | | | 2019-2021 50% of LTIP Award • Opportunity to earn from 0% to 200% of target award based on three-year cumulative Adjusted Net Income (75% weighting) and Operating Revenue (25% weighting) • Risk and reward profile returned to the pre-Business Optimization initiative design, including a payout at 100% for meeting target performance and a 200% maximum payout, consistent with the Committee’s intent when the Business Optimization risk and reward profile was originally implemented in 2017 to cover just the four-year Business Optimization initiative | | | | | ||||||
| | | | | | | | | | 2020-2022 50% of LTIP Award • Opportunity to earn from 0% to 200% of target award based on three-year cumulative Adjusted Net Income (60% weighting) and Operating Revenue (40% weighting) • Increased the weighting of Operating Revenue as a measurement to ensure appropriate focus on our top-line growth • No change to the risk and reward profile, including a payout at 100% for meeting target performance and a 200% maximum payout | |
| | | | Payout Opportunity Prior to 2017 and 2018 | | | 2018 – 2020 Payout Opportunity | |
| Baseline goals | | | 100% of Target Award | | | 75% of Target Award | |
| Maximum for baseline goals | | | 200% of Target Award | | | 150% of Target Award | |
| Significant Business Optimization goals | | | N/A | | | 400% of Target Award | |
| 56 | | | | 2021 Proxy Statement | |
| 58 | | | | 2021 Proxy Statement | |
| Level | | | Multiple of Salary | |
| Chief Executive Officer | | | 6.0 | |
| Executive Vice Presidents | | | 3.0 | |
| Name & Principal Position | | | Year | | | Salary | | | Stock Awards ($)(1) | | | Option Awards ($)(2) | | | Non-Equity Incentive Plan Compensation(3) | | | Change in Pension Value & Non-qualified Deferred Compensation Earnings(4) | | | All Other Compensation(5) | | | Total | | ||||||||||||||||||||||||
| Gail K. Boudreaux President and Chief Executive Officer (CEO) | | | | | 2020 | | | | | $ | 1,400,000 | | | | | $ | 9,000,196 | | | | | $ | 2,999,847 | | | | | $ | 3,270,800 | | | | | | — | | | | | $ | 439,109 | | | | | $ | 17,109,952 | | |
| | | 2019 | | | | | $ | 1,400,000 | | | | | $ | 8,362,743 | | | | | $ | 2,787,303 | | | | | $ | 2,695,000 | | | | | | — | | | | | $ | 228,093 | | | | | $ | 15,473,139 | | | |||
| | | 2018 | | | | | $ | 1,400,000 | | | | | $ | 7,687,717 | | | | | $ | 2,562,332 | | | | | $ | 2,418,150 | | | | | | — | | | | | $ | 116,077 | | | | | $ | 14,184,276 | | | |||
| John E. Gallina EVP and Chief Financial Officer (CFO) | | | | | 2020 | | | | | $ | 845,192 | | | | | $ | 2,437,632 | | | | | $ | 812,385 | | | | | $ | 1,183,269 | | | | | $ | 13,484 | | | | | $ | 109,773 | | | | | $ | 5,401,735 | | |
| | | 2019 | | | | | $ | 820,192 | | | | | $ | 2,437,749 | | | | | $ | 812,264 | | | | | $ | 902,211 | | | | | $ | 17,683 | | | | | $ | 118,954 | | | | | $ | 5,109,053 | | | |||
| | | 2018 | | | | | $ | 794,712 | | | | | $ | 2,437,580 | | | | | $ | 812,445 | | | | | $ | 993,390 | | | | | | — | | | | | $ | 115,739 | | | | | $ | 5,153,866 | | | |||
| Peter D. Haytaian EVP and President, Commercial and Specialty Division | | | | | 2020 | | | | | $ | 845,192 | | | | | $ | 2,437,632 | | | | | $ | 812,385 | | | | | $ | 1,183,269 | | | | | | — | | | | | $ | 108,633 | | | | | $ | 5,387,111 | | |
| | | 2019 | | | | | $ | 820,192 | | | | | $ | 2,437,749 | | | | | $ | 812,264 | | | | | $ | 902,211 | | | | | | — | | | | | $ | 104,550 | | | | | $ | 5,076,966 | | | |||
| | | 2018 | | | | | $ | 794,712 | | | | | $ | 3,437,672 | | | | | $ | 812,445 | | | | | $ | 784,381 | | | | | | — | | | | | $ | 107,333 | | | | | $ | 5,936,543 | | | |||
| Gloria M. McCarthy EVP and Chief Administrative Officer | | | | | 2020 | | | | | $ | 845,192 | | | | | $ | 2,437,632 | | | | | $ | 812,385 | | | | | $ | 1,183,269 | | | | | $ | 143,312 | | | | | $ | 108,871 | | | | | $ | 5,530,661 | | |
| | | 2019 | | | | | $ | 825,000 | | | | | $ | 2,437,749 | | | | | $ | 812,264 | | | | | $ | 907,500 | | | | | $ | 137,889 | | | | | $ | 126,724 | | | | | $ | 5,247,126 | | | |||
| | | 2018 | | | | | $ | 814,904 | | | | | $ | 2,437,580 | | | | | $ | 812,445 | | | | | $ | 1,018,630 | | | | | $ | 146,326 | | | | | $ | 206,902 | | | | | $ | 5,436,787 | | | |||
| Felicia F. Norwood EVP and President, Government Business Division | | | | | 2020 | | | | | $ | 785,577 | | | | | $ | 2,437,632 | | | | | $ | 812,385 | | | | | $ | 1,099,808 | | | | | | — | | | | | $ | 101,001 | | | | | $ | 5,236,403 | | |
| | | 2019 | | | | | $ | 720,192 | | | | | $ | 5,662,903 | | | | | $ | 687,361 | | | | | $ | 792,211 | | | | | | — | | | | | $ | 60,088 | | | | | $ | 7,922,755 | | |
| | | | Restricted Stock Units Granted | | | Performance Stock Units | | ||||||||||||
| Name | | | Target | | | Maximum | | ||||||||||||
| Gail K. Boudreaux | | | | $ | 3,000,246 | | | | | $ | 5,999,950 | | | | | $ | 11,999,900 | | |
| John E. Gallina | | | | $ | 812,725 | | | | | $ | 1,624,907 | | | | | $ | 3,249,815 | | |
| Peter D. Haytaian | | | | $ | 812,725 | | | | | $ | 1,624,907 | | | | | $ | 3,249,815 | | |
| Gloria M. McCarthy | | | | $ | 812,725 | | | | | $ | 1,624,907 | | | | | $ | 3,249,815 | | |
| Felicia F. Norwood | | | | $ | 812,725 | | | | | $ | 1,624,907 | | | | | $ | 3,249,815 | | |
| 60 | | | | 2021 Proxy Statement | |
| Name | | | Tax Equalization(a) | | | Other Perquisites(b) | | | DEC Cash Credits(c) | | | DEC Core Credits(d) | | | 401(k) Plan Match | | | Deferred Compensation Plan Match | | | Total All Other Compensation | | |||||||||||||||||||||
| Gail K. Boudreaux | | | | $ | 200,907 | | | | | | — | | | | | $ | 27,000 | | | | | $ | 26,927 | | | | | $ | 12,825 | | | | | $ | 171,450 | | | | | $ | 439,109 | | |
| John E. Gallina | | | | | — | | | | | $ | 1,140 | | | | | $ | 15,000 | | | | | $ | 15,000 | | | | | $ | 12,825 | | | | | $ | 65,808 | | | | | $ | 109,773 | | |
| Peter D. Haytaian | | | | | — | | | | | | — | | | | | $ | 15,000 | | | | | $ | 15,000 | | | | | $ | 12,825 | | | | | $ | 65,808 | | | | | $ | 108,633 | | |
| Gloria M. McCarthy | | | | | — | | | | | | — | | | | | $ | 15,000 | | | | | $ | 15,000 | | | | | $ | 12,825 | | | | | $ | 66,046 | | | | | $ | 108,871 | | |
| Felicia F. Norwood | | | | | — | | | | | | — | | | | | $ | 15,000 | | | | | $ | 15,000 | | | | | $ | 12,825 | | | | | $ | 58,176 | | | | | $ | 101,001 | | |
| | | | | | | | | | Estimated Future Payouts Under Non-Equity Incentive Plan Awards ($)(1) | | | Estimated Future Payouts Under Equity Incentive Plan Awards (#) | | | All Other Stock Awards: Number of Shares of Stock or Units (#) | | | All Other Option Awards: Number of Securities Underlying Options (#) | | | Exercise Price of Option Awards ($/Share)(2) | | | Grant Date Fair Value of Stock and Option Awards(3) | | ||||||||||||||||||||||||||||||||||||||||||
| Name | | | Grant Date | | | Threshold | | | Target | | | Maximum | | | Threshold | | | Target | | | Maximum | | |||||||||||||||||||||||||||||||||||||||||||||
| Gail K. Boudreaux | | | | | | | | | | $ | 780,000 | | | | | $ | 2,600,000 | | | | | $ | 5,200,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 3/2/2020(4) | | | | | | | | | | | | | | | | | | | | | | | | 0 | | | | | | 22,118 | | | | | | 44,236 | | | | | | | | | | | | | | | | | | | | | | | $ | 5,999,950 | | | |||
| | | 3/2/2020(5) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 11,060 | | | | | | | | | | | | | | | | | $ | 3,000,246 | | | |||
| | | 3/2/2020(6) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 58,809 | | | | | $ | 271.27 | | | | | $ | 2,999,847 | | | |||
| John E. Gallina | | | | | | | | | | $ | 253,558 | | | | | $ | 845,192 | | | | | $ | 1,690,384 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 3/2/2020(4) | | | | | | | | | | | | | | | | | | | | | | | | 0 | | | | | | 5,990 | | | | | | 11,980 | | | | | | | | | | | | | | | | | | | | | | | $ | 1,624,907 | | | |||
| | | 3/2/2020(5) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,996 | | | | | | | | | | | | | | | | | $ | 812,725 | | | |||
| | | 3/2/2020(6) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 15,926 | | | | | $ | 271.27 | | | | | $ | 812,385 | | | |||
| Peter D. Haytaian | | | | | | | | | | $ | 253,558 | | | | | $ | 845,192 | | | | | $ | 1,690,384 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 3/2/2020(4) | | | | | | | | | | | | | | | | | | | | | | | | 0 | | | | | | 5,990 | | | | | | 11,980 | | | | | | | | | | | | | | | | | | | | | | | $ | 1,624,907 | | | |||
| | | 3/2/2020(5) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,996 | | | | | | | | | | | | | | | | | $ | 812,725 | | | |||
| | | 3/2/2020(6) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 15,926 | | | | | $ | 271.27 | | | | | $ | 812,385 | | | |||
| Gloria M. McCarthy | | | | | | | | | | $ | 253,558 | | | | | $ | 845,192 | | | | | $ | 1,690,384 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 3/2/2020(4) | | | | | | | | | | | | | | | | | | | | | | | | 0 | | | | | | 5,990 | | | | | | 11,980 | | | | | | | | | | | | | | | | | | | | | | | $ | 1,624,907 | | | |||
| | | 3/2/2020(5) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,996 | | | | | | | | | | | | | | | | | $ | 812,725 | | | |||
| | | 3/2/2020(6) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 15,926 | | | | | $ | 271.27 | | | | | $ | 812,385 | | | |||
| Felicia F. Norwood | | | | | | | | | | $ | 235,673 | | | | | $ | 785,577 | | | | | $ | 1,571,154 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 3/2/2020(4) | | | | | | | | | | | | | | | | | | | | | | | | 0 | | | | | | 5,990 | | | | | | 11,980 | | | | | | | | | | | | | | | | | | | | | | | $ | 1,624,907 | | | |||
| | | 3/2/2020(5) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,996 | | | | | | | | | | | | | | | | | $ | 812,725 | | | |||
| | | 3/2/2020(6) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 15,926 | | | | | $ | 271.27 | | | | | $ | 812,385 | | |
| 62 | | | | 2021 Proxy Statement | |
| | | | Option Awards | | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||
| Name | | | Number of Securities Underlying Unexercised Options Exercisable (#) | | | Number of Securities Underlying Unexercised Options Unexercisable (#)(1) | | | Option Exercise Price ($/Share) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#)(2) | | | Market Value of Shares or Units of Stock That Have Not Vested ($)(3) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)(2) | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)(3) | | ||||||||||||||||||||||||
| Gail K. Boudreaux | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 94,022 | | | | | $ | 30,189,524 | | | | | | 40,238 | | | | | $ | 12,920,019 | | |
| | | 38,795 | | | | | | 7,759 | | | | | $ | 232.04 | | | | | | 3/1/28 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | 13,940 | | | | | | 27,880 | | | | | $ | 307.68 | | | | | | 3/1/29 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | — | | | | | | 58,809 | | | | | $ | 271.27 | | | | | | 3/2/30 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| John E. Gallina | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 29,147 | | | | | $ | 9,358,810 | | | | | | 11,272 | | | | | $ | 3,619,326 | | |
| | | 5,775 | | | | | | — | | | | | $ | 146.93 | | | | | | 3/2/25 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | 1,962 | | | | | | — | | | | | $ | 131.80 | | | | | | 3/1/26 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | 4,038 | | | | | | — | | | | | $ | 132.51 | | | | | | 6/1/26 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | 19,908 | | | | | | — | | | | | $ | 166.97 | | | | | | 3/1/27 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | 12,300 | | | | | | 2,461 | | | | | $ | 232.04 | | | | | | 3/1/28 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | 4,062 | | | | | | 8,125 | | | | | $ | 307.68 | | | | | | 3/1/29 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | — | | | | | | 15,926 | | | | | $ | 271.27 | | | | | | 3/2/30 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| Peter D. Haytaian | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 33,457 | | | | | $ | 10,742,708 | | | | | | 11,272 | | | | | $ | 3,619,326 | | |
| | | 15,593 | | | | | | — | | | | | $ | 146.93 | | | | | | 3/2/25 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | 24,348 | | | | | | — | | | | | $ | 131.80 | | | | | | 3/1/26 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | 19,908 | | | | | | — | | | | | $ | 166.97 | | | | | | 3/1/27 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | 12,300 | | | | | | 2,461 | | | | | $ | 232.04 | | | | | | 3/1/28 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | 4,062 | | | | | | 8,125 | | | | | $ | 307.68 | | | | | | 3/1/29 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | — | | | | | | 15,926 | | | | | $ | 271.27 | | | | | | 3/2/30 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| Gloria M. McCarthy | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 29,147 | | | | | $ | 9,358,810 | | | | | | 11,272 | | | | | $ | 3,619,326 | | |
| | | 2,175 | | | | | | — | | | | | $ | 122.90 | | | | | | 10/3/26 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | 15,314 | | | | | | — | | | | | $ | 166.97 | | | | | | 3/1/27 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | 4,606 | | | | | | — | | | | | $ | 166.49 | | | | | | 4/3/27 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | 12,300 | | | | | | 2,461 | | | | | $ | 232.04 | | | | | | 3/1/28 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | 4,062 | | | | | | 8,125 | | | | | $ | 307.68 | | | | | | 3/1/29 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | — | | | | | | 15,926 | | | | | $ | 271.27 | | | | | | 3/2/30 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| Felicia F. Norwood | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 24,774 | | | | | $ | 7,954,684 | | | | | | 10,459 | | | | | $ | 3,358,280 | | |
| | | 5,010 | | | | | | 2,506 | | | | | $ | 238.27 | | | | | | 7/2/28 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | 3,437 | | | | | | 6,876 | | | | | $ | 307.68 | | | | | | 3/1/29 | | | | | | | | | | | | | | | | | | | | | | | | | | | |||
| | | — | | | | | | 15,926 | | | | | $ | 271.27 | | | | | | 3/2/30 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Option Expiration Date | | | Vesting Schedule | |
| 3/1/28 | | | All shares vest on March 1, 2021 | |
| 7/2/28 | | | All shares vest on July 2, 2021 | |
| 3/1/29 | | | Vests in equal installments on March 1, 2021 and March 1, 2022 | |
| 3/2/30 | | | Vests in equal installments on March 2, 2021, March 2, 2022 and March 2, 2023 | |
| Name | | | Vesting Date | | | Restricted Stock Units | | | Performance Share Units Granted in 2018(i) | | | Performance Share Units Granted in 2019 | | | Performance Share Units Granted in 2020 | | |||||||||||||||
| Gail K. Boudreaux | | | | | 3/1/2021 | | | | | | 6,702 | | | | | | 73,240 | | | | | | — | | | | | | — | | |
| | | 3/2/2021 | | | | | | 3,686 | | | | | | — | | | | | | — | | | | | | — | | | |||
| | | 3/1/2022 | | | | | | 3,020 | | | | | | — | | | | | | 18,120 | | | | | | — | | | |||
| | | 3/2/2022 | | | | | | 3,687 | | | | | | — | | | | | | — | | | | | | — | | | |||
| | | 3/2/2023 | | | | | | 3,687 | | | | | | — | | | | | | — | | | | | | 22,118 | | | |||
| John E. Gallina | | | | | 3/1/2021 | | | | | | 2,048 | | | | | | 23,222 | | | | | | — | | | | | | — | | |
| | | 3/2/2021 | | | | | | 998 | | | | | | — | | | | | | — | | | | | | — | | | |||
| | | 3/1/2022 | | | | | | 881 | | | | | | — | | | | | | 5,282 | | | | | | — | | | |||
| | | 3/2/2022 | | | | | | 999 | | | | | | — | | | | | | — | | | | | | — | | | |||
| | | 3/2/2023 | | | | | | 999 | | | | | | — | | | | | | — | | | | | | 5,990 | | | |||
| Peter D. Haytaian | | | | | 3/1/2021 | | | | | | 6,358 | | | | | | 23,222 | | | | | | — | | | | | | — | | |
| | | 3/2/2021 | | | | | | 998 | | | | | | — | | | | | | — | | | | | | — | | | |||
| | | 3/1/2022 | | | | | | 881 | | | | | | — | | | | | | 5,282 | | | | | | — | | | |||
| | | 3/2/2022 | | | | | | 999 | | | | | | — | | | | | | — | | | | | | — | | | |||
| | | 3/2/2023 | | | | | | 999 | | | | | | — | | | | | | — | | | | | | 5,990 | | | |||
| Gloria M. McCarthy | | | | | 3/1/2021 | | | | | | 2,048 | | | | | | 23,222 | | | | | | — | | | | | | — | | |
| | | 3/2/2021 | | | | | | 998 | | | | | | — | | | | | | — | | | | | | — | | | |||
| | | 3/1/2022 | | | | | | 881 | | | | | | — | | | | | | 5,282 | | | | | | — | | | |||
| | | 3/2/2022 | | | | | | 999 | | | | | | — | | | | | | — | | | | | | — | | | |||
| | | 3/2/2023 | | | | | | 999 | | | | | | — | | | | | | — | | | | | | 5,990 | | | |||
| Felicia F. Norwood | | | | | 3/1/2021 | | | | | | 745 | | | | | | — | | | | | | — | | | | | | — | | |
| | | 3/2/2021 | | | | | | 998 | | | | | | — | | | | | | — | | | | | | — | | | |||
| | | 7/2/2021 | | | | | | 595 | | | | | | 11,831 | | | | | | — | | | | | | — | | | |||
| | | 12/30/2021 | | | | | | 3,931 | | | | | | — | | | | | | — | | | | | | — | | | |||
| | | 3/1/2022 | | | | | | 745 | | | | | | — | | | | | | 4,469 | | | | | | — | | | |||
| | | 3/2/2022 | | | | | | 999 | | | | | | — | | | | | | — | | | | | | — | | | |||
| | | 12/30/2022 | | | | | | 3,931 | | | | | | — | | | | | | — | | | | | | — | | | |||
| | | 3/2/2023 | | | | | | 999 | | | | | | — | | | | | | — | | | | | | 5,990 | | |
| 64 | | | | 2021 Proxy Statement | |
| | | | Option Awards | | | Stock Awards(1) | | ||||||||||||||||||
| Name | | | Number of Shares Acquired on Exercise (#) | | | Value Realized Upon Exercise ($) | | | Number of Shares Acquired on Vesting (#) | | | Value Realized On Vesting ($)(2) | | ||||||||||||
| Gail K. Boudreaux | | | | | — | | | | | | — | | | | | | 39,803 | | | | | $ | 12,563,729 | | |
| John E. Gallina | | | | | — | | | | | | — | | | | | | 41,090 | | | | | $ | 11,504,018 | | |
| Peter D. Haytaian | | | | | 28,296 | | | | | $ | 5,451,093 | | | | | | 41,090 | | | | | $ | 11,504,018 | | |
| Gloria M. McCarthy | | | | | 18,261 | | | | | $ | 2,635,201 | | | | | | 41,091 | | | | | $ | 10,821,915 | | |
| Felicia F. Norwood | | | | | — | | | | | | — | | | | | | 5,270 | | | | | $ | 1,624,270 | | |
| Name | | | Plan Name | | | Number of Years of Credited Service (#)(1) | | | Present Value of Accumulated Benefit ($)(2) | | | Payments During the Last Fiscal Year ($) | |
| Gail K. Boudreaux | | | N/A | | | — | | | — | | | — | |
| John E. Gallina | | | Anthem Cash Balance Plan A | | | 11.58 | | | $218,990 | | | — | |
| | | | Total | | | | | | $218,990 | | | — | |
| Peter D. Haytaian | | | N/A | | | — | | | — | | | — | |
| Gloria M. McCarthy | | | Anthem Cash Balance Plan B | | | 44.58 | | | $1,428,908 | | | — | |
| | | | Empire Blue Cross and Blue Shield Supplemental Cash Balance Pension Plan | | | 44.58 | | | $2,383,451 | | | — | |
| | | | Total | | | | | | $3,812,359 | | | — | |
| Felicia F. Norwood | | | N/A | | | — | | | — | | | — | |
| 66 | | | | 2021 Proxy Statement | |
| Name | | | Executive Contributions in Last Fiscal Year(1) | | | Anthem Contributions in Last Fiscal Year(2) | | | Aggregated Earnings in Last Fiscal Year | | | Aggregated Withdrawals / Distributions | | | Aggregated Balance at Last Fiscal Year End(3) | | |||||||||||||||
| Gail K. Boudreaux | | | | $ | 229,546 | | | | | $ | 171,450 | | | | | $ | 341,718 | | | | | | — | | | | | $ | 1,571,061 | | |
| John E. Gallina | | | | $ | 158,875 | | | | | $ | 65,808 | | | | | $ | 524,832 | | | | | | — | | | | | $ | 3,330,206 | | |
| Peter D. Haytaian | | | | $ | 95,325 | | | | | $ | 65,808 | | | | | $ | 95,802 | | | | | | — | | | | | $ | 671,495 | | |
| Gloria M. McCarthy | | | | $ | 95,642 | | | | | $ | 66,046 | | | | | $ | 1,023,516 | | | | | | — | | | | | $ | 9,630,460 | | |
| Felicia F. Norwood | | | | $ | 86,302 | | | | | $ | 58,176 | | | | | $ | 38,006 | | | | | | — | | | | | $ | 268,126 | | |
| | | | Cash Severance | | | AIP Award for Year of Termination | | | Acceleration or Continuation of Equity Awards(1) | | | Continuation of Executive Benefits | | | Continuation of Health & Life Insurance Coverage(2) | | | Post Termination Benefits(3) | | | Total Post Termination Payment & Benefit Value | | |||||||||||||||||||||
| Gail K. Boudreaux | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Termination without Cause or for Good Reason following a change-in-control(4) | | | | $ | 12,540,000 | | | | | $ | 3,270,800 | | | | | $ | 47,104,218 | | | | | $ | 162,000 | | | | | $ | 34,296 | | | | | $ | 7,750 | | | | | $ | 63,119,064 | | |
| Termination without Cause or for Good Reason(5) | | | | $ | 8,000,000 | | | | | $ | 3,270,800 | | | | | $ | 22,336,158 | | | | | $ | 108,000 | | | | | $ | 22,864 | | | | | $ | 7,750 | | | | | $ | 33,745,572 | | |
| Retirement(6) | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| Resignation(7) | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| Death | | | | | — | | | | | $ | 3,270,800 | | | | | $ | 30,679,501 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 33,950,301 | | |
| Long Term Disability | | | | | — | | | | | $ | 3,270,800 | | | | | $ | 30,679,501 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 33,950,301 | | |
| For Cause | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| John E. Gallina | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Termination without Cause or for Good Reason following a change-in-control(4) | | | | $ | 5,329,500 | | | | | $ | 1,183,269 | | | | | $ | 14,099,678 | | | | | $ | 90,000 | | | | | $ | 34,296 | | | | | $ | 7,750 | | | | | $ | 20,744,493 | | |
| Termination without Cause or for Good Reason(5) | | | | $ | 3,400,000 | | | | | $ | 1,183,269 | | | | | $ | 12,252,448 | | | | | $ | 60,000 | | | | | $ | 22,864 | | | | | $ | 7,750 | | | | | $ | 16,926,331 | | |
| Retirement(6) | | | | | — | | | | | $ | 1,183,269 | | | | | $ | 12,252,448 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 13,435,717 | | |
| Resignation(7) | | | | | — | | | | | $ | 1,183,269 | | | | | $ | 12,252,448 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 13,435,717 | | |
| Death | | | | | — | | | | | $ | 1,183,269 | | | | | $ | 8,891,920 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 10,075,189 | | |
| Long Term Disability | | | | | — | | | | | $ | 1,183,269 | | | | | $ | 8,891,920 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 10,075,189 | | |
| For Cause | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| Peter D. Haytaian | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Termination without Cause or for Good Reason following a change-in-control(4) | | | | $ | 5,329,500 | | | | | $ | 1,183,269 | | | | | $ | 15,483,576 | | | | | $ | 90,000 | | | | | $ | 34,296 | | | | | $ | 7,750 | | | | | $ | 22,128,391 | | |
| Termination without Cause or for Good Reason(5) | | | | $ | 3,400,000 | | | | | $ | 1,183,269 | | | | | $ | 6,614,986 | | | | | $ | 60,000 | | | | | $ | 22,864 | | | | | $ | 7,750 | | | | | $ | 11,288,869 | | |
| Retirement(6) | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| Resignation(7) | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| Death | | | | | — | | | | | $ | 1,183,269 | | | | | $ | 10,275,818 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 11,459,087 | | |
| Long Term Disability | | | | | — | | | | | $ | 1,183,269 | | | | | $ | 10,275,818 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 11,459,087 | | |
| For Cause | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| 68 | | | | 2021 Proxy Statement | |
| | | | Cash Severance | | | AIP Award for Year of Termination | | | Acceleration or Continuation of Equity Awards(1) | | | Continuation of Executive Benefits | | | Continuation of Health & Life Insurance Coverage(2) | | | Post Termination Benefits(3) | | | Total Post Termination Payment & Benefit Value | | |||||||||||||||||||||
| Gloria M. McCarthy | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Termination without Cause or for Good Reason following a change-in-control(4) | | | | $ | 5,329,500 | | | | | $ | 1,183,269 | | | | | $ | 14,099,678 | | | | | $ | 90,000 | | | | | $ | 34,296 | | | | | $ | 7,750 | | | | | $ | 20,744,493 | | |
| Termination without Cause or for Good Reason(5) | | | | $ | 3,400,000 | | | | | $ | 1,183,269 | | | | | $ | 12,252,448 | | | | | $ | 60,000 | | | | | $ | 22,864 | | | | | $ | 7,750 | | | | | $ | 16,926,331 | | |
| Retirement(6) | | | | | — | | | | | $ | 1,183,269 | | | | | $ | 12,252,448 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 13,435,717 | | |
| Resignation(7) | | | | | — | | | | | $ | 1,183,269 | | | | | $ | 12,252,448 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 13,435,717 | | |
| Death | | | | | — | | | | | $ | 1,183,269 | | | | | $ | 8,891,920 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 10,075,189 | | |
| Long Term Disability | | | | | — | | | | | $ | 1,183,269 | | | | | $ | 8,891,920 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 10,075,189 | | |
| For Cause | | | | �� | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| Felicia F. Norwood | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Termination without Cause or for Good Reason following a change-in-control(4) | | | | $ | 3,344,000 | | | | | $ | 1,099,808 | | | | | $ | 12,406,151 | | | | | $ | 0 | | | | | $ | 22,864 | | | | | $ | 7,750 | | | | | $ | 16,880,573 | | |
| Termination without Cause or for Good Reason(5) | | | | $ | 3,200,000 | | | | | $ | 1,099,808 | | | | | $ | 9,428,446 | | | | | $ | 0 | | | | | $ | 22,864 | | | | | $ | 7,750 | | | | | $ | 13,758,868 | | |
| Retirement(6) | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| Resignation(7) | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| Death | | | | | — | | | | | $ | 1,099,808 | | | | | $ | 9,752,985 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 10,852,793 | | |
| Long Term Disability | | | | | — | | | | | $ | 1,099,808 | | | | | $ | 9,752,985 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 10,852,793 | | |
| For Cause | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| 70 | | | | 2021 Proxy Statement | |
| PROPOSAL 3 | |
| Ratification of the Appointment of Independent Registered Public Accounting Firm | |
| | | |||
| | | The Board of Directors unanimously recommends a vote FOR Proposal 3, the ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2021. | |
| 72 | | | | 2021 Proxy Statement | |
| | | | Fiscal Year | | |||||||||
| Fee Category | | | 2020 | | | 2019 | | ||||||
| Audit fees(1) | | | | $ | 14,945,000 | | | | | $ | 13,681,000 | | |
| Audit-related fees(2) | | | | | 3,780,000 | | | | | | 2,318,000 | | |
| Tax fees(3) | | | | | 730,000 | | | | | | 242,000 | | |
| All other fees(4) | | | | | 13,000 | | | | | | 20,000 | | |
| Total: | | | | $ | 19,468,000 | | | | | $ | 16,261,000 | | |
| 74 | | | | 2021 Proxy Statement | |
| Name and Address of Beneficial Owner | | | Amount and Nature of Beneficial Ownership | | | Percent of Class | | |||
| BlackRock, Inc.(1) 55 East 52nd Street New York, NY 10055 | | | | | 22,413,809 | | | | 9.0% | |
| The Vanguard Group(2) 100 Vanguard Boulevard Malvern, PA 19355 | | | | | 18,954,574 | | | | 7.6% | |
| Name | | | Number of Shares Owned(1) | | | Number of Shares Supplementally Owned(2) | | | Total Number of Shares Beneficially Owned | | | Percent of Class | | ||||||||||||
| R. Kerry Clark | | | | | — | | | | | | 7,261 | | | | | | 7,261 | | | | | | * | | |
| Robert L. Dixon, Jr. | | | | | 5,065 | | | | | | 4,503 | | | | | | 9,568 | | | | | | * | | |
| Lewis Hay, III | | | | | — | | | | | | 9,128 | | | | | | 9,128 | | | | | | * | | |
| Julie A. Hill | | | | | — | | | | | | 32,521 | | | | | | 32,521 | | | | | | * | | |
| Bahija Jallal | | | | | — | | | | | | 2,409 | | | | | | 2,409 | | | | | | * | | |
| Antonio F. Neri | | | | | — | | | | | | 2,546 | | | | | | 2,546 | | | | | | * | | |
| Ramiro G. Peru | | | | | 6,267 | | | | | | 4,503 | | | | | | 10,770 | | | | | | * | | |
| Ryan M. Schneider | | | | | — | | | | | | 1,221 | | | | | | 1,221 | | | | | | * | | |
| Elizabeth E. Tallett | | | | | — | | | | | | 8,513 | | | | | | 8,513 | | | | | | * | | |
| Gail K. Boudreaux(3) | | | | | 126,988 | | | | | | 83,578 | | | | | | 210,566 | | | | | | * | | |
| John E. Gallina | | | | | 93,155 | | | | | | 26,268 | | | | | | 119,423 | | | | | | * | | |
| Peter D. Haytaian | | | | | 110,449 | | | | | | 30,578 | | | | | | 141,027 | | | | | | * | | |
| Gloria M. McCarthy | | | | | 86,462 | | | | | | 26,268 | | | | | | 112,730 | | | | | | * | | |
| Felicia F. Norwood | | | | | 20,678 | | | | | | 1,743 | | | | | | 22,421 | | | | | | * | | |
| Other Executive Officers | | | | | 24,921 | | | | | | 5,673 | | | | | | 30,594 | | | | | | * | | |
| All current directors and executive officers as a group (18 persons) | | | | | 473,985 | | | | | | 246,713 | | | | | | 720,698 | | | | | | * | | |
| 76 | | | | 2021 Proxy Statement | |
| By Internet | | | If you are a shareholder of record, you may vote through the internet by going to www.envisionreports.com/antm and following the instructions. You will need to have the E-Proxy Notice or, if you received a printed copy of the proxy materials, your proxy card, available when voting. If you are a beneficial owner, you may vote through the internet by going to www.proxyvote.com and following the instructions. If you vote through the internet, you do not need to return a proxy card or voting instruction form. | |
| By Telephone | | | If you are a shareholder of record, you may vote by touchtone telephone by calling (800) 652-8683 in the United States, U.S. territories or Canada or (781) 575-2300 from outside the United States, U.S. territories and Canada. If you are a beneficial owner, please vote by using the telephone number that is shown on your voting instruction form. You will need to have your E-Proxy Notice or, if you received a printed copy of the proxy materials, your proxy card or voting instruction form, available when voting. If you vote by telephone, you do not need to return a proxy card or voting instruction form. | |
| By Mail | | | If you received a printed copy of our proxy materials, you may vote by signing and dating your proxy card or voting instruction form and mailing it in the enclosed postage-prepaid envelope. If you received the E-Proxy Notice and would like to obtain a proxy card or voting instruction form, please follow the instructions on the E-Proxy Notice for requesting a paper or email copy of our proxy materials. | |
| With Your Smartphone | | | Scan the QR code that is located on your proxy card, E-Proxy Notice or voting instruction form to vote with your smartphone. | |
| Through the Live Audio Webcast of the Annual Meeting of Shareholders | | | If you are a shareholder of record and have already voted your shares through one of the methods outlined above, there is no need to vote those shares during the meeting. If you are a shareholder of record and have not voted your shares prior to the meeting as outlined above, you may log in to the live audio webcast with your control number located on your proxy card or E-Proxy Notice to vote during the meeting. If you are a beneficial owner and have not voted your shares prior to the meeting as outlined above, you may log in to the live audio webcast with your control number located on your voting instruction form or E-Proxy Notice to vote during the meeting. Alternatively, you may contact your bank, broker or nominee and request a legal proxy and then register in advance no later than 5:00 p.m., Eastern Daylight Time, on May 21, 2021 to vote at the annual meeting. If you choose to request a legal proxy, any previous vote will be revoked, and you will need to revote at the annual meeting. | |
| 78 | | | | 2021 Proxy Statement | |
| | virtual annual meeting via live audio webcast | | | | Meeting Date and Time: Wednesday, May 26, 2021 at 9:00 a.m. Eastern Daylight Time Meeting Access: www.meetingcenter.io/267442224 Meeting Password: ANTM2021 The audio webcast is compatible with all common web browsers and may be viewed on mobile devices. Online access to the audio webcast will open 15 minutes prior to the start of the annual meeting to allow time to log in and test your device’s audio system. We encourage you to access the meeting in advance of the designated start time. After log in, click on the Broadcast Bar to listen to the webcast. | | |
| | how to participate in the annual meeting as a shareholder | | | | To log in to the webcast as a shareholder of record or an associate shareholder, visit the meeting access link. You will be asked to accept Computershare’s Terms and Conditions and Privacy Policy. Click “I have a Control Number” and provide your control number from your E-Proxy Notice or proxy card and the meeting password as your login. If you are a beneficial owner and you would like to participate as a shareholder, you have two options. First, you may log in to the live audio webcast with your control number located on your voting instruction form or E-Proxy notice provided by your broker, bank or nominee. Alternatively, you may register in advance, which will require to you to contact your bank, broker, or other nominee and request a legal proxy, and you must submit the legal proxy along with your name and email address to Computershare at legalproxy@computershare.com. Requests for registration must be labeled “Legal Proxy” in the subject line and be received no later than 5:00 p.m., Eastern Daylight Time, on May 21, 2021. You will receive a confirmation email from Computershare of your registration with a control number that may be used with the meeting access link above to join the annual meeting as a shareholder. | | |
| | how to participate in the annual meeting as a guest without a control number | | | | To log in to the webcast as a guest, visit the meeting access link. You will be asked to accept Computershare’s Terms and Conditions and Privacy Policy. Click “Join as a Guest” and provide your first and last name and your email address. If you attend as a guest, you will not have the option to vote your shares or submit questions during the meeting. | | |
| | how to participate without internet access | | | | If you do not have internet access and want to listen to the annual meeting, please contact Anthem Shareholder Services at shareholder.services@anthem.com or call (800) 985-0999 by no later than 5:00 p.m., Eastern Daylight Time, on May 21, 2021 for alternative access instructions. You will not be able to vote your shares during the meeting. | | |
| | agenda and rules of conduct | | | | The meeting agenda and rules of conduct and procedures will be posted to the webcast portal and available to shareholders and guests. | | |
| | technical difficulties and general questions about the annual meeting | | | | For technical difficulties logging into the webcast, click the “Attendance Instruction” button that is located on the meeting webcast, which will provide a phone number for assistance: US & Canada: (888) 724-2416 and Other: (781) 575-2748. This link also will provide system requirements. For technical difficulties once logged into the webcast, click the “Help” button in the upper right hand side of the Broadcast screen from within the live webcast of the annual meeting. For general questions about the annual meeting, email Anthem Shareholder Services at shareholder.services@anthem.com or call (800) 985-0999. | | |
| 80 | | | | 2021 Proxy Statement | |
| 82 | | | | 2021 Proxy Statement | |
| (In millions, except per share data) | | | Year Ended December 31, 2020 | | | Year Ended December 31, 2019 | | | Year Ended December 31, 2018 | | |||||||||
| Net income | | | | $ | 4,572 | | | | | $ | 4,807 | | | | | $ | 3,750 | | |
| Add / (Subtract): | | | | | | | | | | | | | | | | | | | |
| Net realized (gains)/losses on financial instruments | | | | | (182) | | | | | | (67) | | | | | | 206 | | |
| Amortization of other intangible assets | | | | | 361 | | | | | | 338 | | | | | | 358 | | |
| Business optimization charges | | | | | 653 | | | | | | — | | | | | | — | | |
| BCBSA litigation settlement | | | | | 548 | | | | | | — | | | | | | — | | |
| Transaction and integration related costs | | | | | 49 | | | | | | 11 | | | | | | 9 | | |
| Litigation expenses | | | | | 40 | | | | | | 52 | | | | | | — | | |
| Loss on extinguishment of debt | | | | | 36 | | | | | | 2 | | | | | | 11 | | |
| Tax impact of non-GAAP adjustments | | | | | (360) | | | | | | (84) | | | | | | (135) | | |
| Net adjustment items | | | | | 1,145 | | | | | | 252 | | | | | | 449 | | |
| Adjusted net income | | | | $ | 5,717 | | | | | $ | 5,059 | | | | | $ | 4,199 | | |
| Net income per diluted share | | | | $ | 17.98 | | | | | $ | 18.47 | | | | | $ | 14.19 | | |
| Add / (Subtract): | | | | | | | | | | | | | | | | | | | |
| Net realized (gains)/losses on financial instruments | | | | | (0.72) | | | | | | (0.26) | | | | | | 0.78 | | |
| Amortization of other intangible assets | | | | | 1.42 | | | | | | 1.30 | | | | | | 1.36 | | |
| Business optimization charges | | | | | 2.57 | | | | | | — | | | | | | — | | |
| BCBSA litigation settlement | | | | | 2.15 | | | | | | — | | | | | | — | | |
| Transaction and integration related costs | | | | | 0.19 | | | | | | 0.04 | | | | | | 0.03 | | |
| Litigation expenses | | | | | 0.16 | | | | | | 0.20 | | | | | | — | | |
| Loss on extinguishment of debt | | | | | 0.14 | | | | | | 0.01 | | | | | | 0.04 | | |
| Tax impact of non-GAAP adjustments | | | | | (1.42) | | | | | | (0.32) | | | | | | (0.51) | | |
| Rounding impact | | | | | 0.01 | | | | | | — | | | | | | — | | |
| Net adjustment items | | | | | 4.50 | | | | | | 0.97 | | | | | | 1.70 | | |
| Adjusted net income per diluted share | | | | $ | 22.48 | | | | | $ | 19.44 | | | | | $ | 15.89 | | |
| Income before income tax expense | | | | $ | 6,238 | | | | | $ | 5,985 | | | | | $ | 5,068 | | |
| Add / (Subtract) | | | | | | | | | | | | | | | | | | | |
| Net investment income | | | | | (877) | | | | | | (1,005) | | | | | | (970) | | |
| Net realized (gains)/losses on financial instruments | | | | | (182) | | | | | | (67) | | | | | | 206 | | |
| Interest expense | | | | | 784 | | | | | | 746 | | | | | | 753 | | |
| Amortization of other intangible assets | | | | | 361 | | | | | | 338 | | | | | | 358 | | |
| Loss on extinguishment of debt | | | | | 36 | | | | | | 2 | | | | | | 11 | | |
| Net adjustment items | | | | | 122 | | | | | | 14 | | | | | | 358 | | |
| Operating Gain | | | | $ | 6,360 | | | | | $ | 5,999 | | | | | $ | 5,426 | | |
| | | | |||||
| Anthem, Inc. was named to the 2020 Dow Jones Sustainability North America and World Indices (DJSI). This marks the third consecutive year Anthem has been recognized by the DJSI for leadership in sustainability. | | | Anthem, Inc. is committed to supporting gender equality and was included in the 2021 Bloomberg Gender-Equality Index for the second consecutive year. | | |||
| | | | |||||
| Anthem, Inc. was included in the Forbes JUST 100 list for a second consecutive year, continuing to rank first in the health care providers and services category. | | | Anthem, Inc. was included in the FTSE4Good Index (FTSE Russell), 2018 – 2020. | | |||
| Anthem, Inc. was recognized in 2020 as a Great Place to Work with 83% of associates saying that Anthem is a great place to work. | | | Anthem, Inc. was recognized for diversity best practices by the Working Mother Research Institute, 2017 – 2020. | | |||
| Anthem, Inc. was recognized as a Military Friendly Employer, 2010 – 2021. | | | Anthem, Inc. was recognized as a Leading Disability Employer by the National Organization on Disability, 2017 – 2020. | | |||
| | | | | | |||
| Anthem, Inc. has a perfect 1/1/1 QualityScore from Institutional Shareholder Services (ISS), ranking first in the managed healthcare sector (as of February 2021). | | | Anthem, Inc. has been named a 2021 ESG Industry Top-Rated Company by Sustainalytics. In addition, Anthem is ranked first in the managed healthcare subindustry for lowest ESG risk and second out of nearly 500 global companies in the healthcare industry (as of February 2021). | |